

# Butyrophilin and Butyrophilin-like genes and their role in epithelial cell-intraepithelial T lymphocyte cross-talk

Cristina Lebrero Fernández

Department of Microbiology and Immunology  
Institute of Biomedicine  
Sahlgrenska Academy at University of Gothenburg



UNIVERSITY OF GOTHENBURG

Gothenburg 2016

Cover illustration: Gut with magnifying glass showing the intestinal epithelium, where the interaction between the intraepithelial T lymphocytes and the neighboring epithelial cells is poorly defined, by Cristina Lebrero Fernández.

iEC: intestinal epithelial cell; IEL: intraepithelial lymphocyte.

Butyrophilin and Butyrophilin-like genes and their role in epithelial cell-intraepithelial T lymphocyte cross-talk

© Cristina Lebrero Fernández 2016

[cristina.lebrero@gu.se](mailto:cristina.lebrero@gu.se)

ISBN: 978-91-628-9756-7

ISBN: 978-91-628-9757-4 (e-pub)

<http://hdl.handle.net/2077/41848>

Printed by Ineko AB, Kållerød, Sweden 2016

To my family



# Butyrophilin and Butyrophilin-like genes and their role in epithelial cell-intraepithelial T lymphocyte cross-talk

Cristina Lebrero Fernández

Department of Microbiology and Immunology, Institute of Biomedicine  
Sahlgrenska Academy at University of Gothenburg  
Gothenburg, Sweden

## ABSTRACT

More than 50% of our immune system is located in the gut. The intestinal epithelium, which forms an interface between the organism and the environment, harbors intraepithelial lymphocytes (IELs) that comprise a mixture of conventional  $\alpha\beta$  T cells and unconventional  $\alpha\beta$ - and  $\gamma\delta$  T cells. IELs play important roles in regulation of gut epithelial integrity and in recognition of stressed and infected epithelial cells, and thus, are critical effector components of mucosal immunity. However, the understanding of the IEL function and their interaction with the neighboring epithelial cells is still limited. The aim of this thesis was to investigate how the Butyrophilin (Btn) and Butyrophilin-like (Btl) molecules are involved in the epithelial cell – IEL cross-talk and hence, to characterize their role in regulating local T cell mediated immune responses in the intestinal mucosa.

Btn and Btl proteins have over the past decade emerged as novel regulators of T cell functions both in periphery and locally in the tissue, and have been shown to be genetically associated with various inflammatory and proliferative disorders. We have reported the ability of intestinal epithelial cell (iEC)-specific Btl proteins to induce IEL activation and proliferation in conditions without exogenous stimulation, which may contribute to the upkeep of the intestinal IEL pool. We have furthermore identified novel intestinal epithelial cell expressed Btl- heteromeric protein complexes, and demonstrated that one of them, the Btl1-Btl6 heteromeric complex, specifically enhances the expansion of intestinal IELs bearing the V $\gamma$ 7V $\delta$ 4 receptor *in vitro*. We have additionally explored how iEC-specific Btl proteins are regulated in the neonatal murine small intestine and found that Btl- protein expression is delayed in the ontogeny and that the expression of the *Btl* genes is regulated on post-transcriptional level. Our data demonstrate that the proteins are not detectable in the small intestinal epithelium of mice before 3 weeks of age, and that the appearance of Btl1 and Btl6 proteins correlates with the expansion of intestinal V $\gamma$ 7V $\delta$ 4 IELs, further adding strength to our *in vitro* results. Since  $\gamma\delta$  IELs are essential for

the maintenance of the homeostasis in the gut, our findings suggest that Btl proteins have implications in the intestinal immune response. To increase the understanding of the Btl and Btl molecules' role in intestinal disorders, we have characterized the expression of human and mouse Btl and Btl genes in colonic inflammation and intestinal tumors. Our results show an altered expression of the *BTN* and *BTNL* genes in these diseases and indicate an association between Btl and Btl genes and ulcerative colitis and colon cancer.

In summary, this thesis work has demonstrated that iEC-specific Btl proteins can regulate the function of intestinal intraepithelial lymphocytes in the gut, and that Btl and Btl genes are associated with bowel pathology. Nonetheless, further studies are necessary to identify the complete immunomodulatory implication of the Btl and Btl family members in healthy and inflamed/infected gut mucosa.

**Keywords:** butyrophilin-like, butyrophilin, intraepithelial lymphocytes, mucosal immunity, intestinal epithelial cells,  $\gamma\delta$  T cells, intestinal inflammation, colon cancer, ulcerative colitis.

**ISBN:** 978-91-628-9756-7

<http://hdl.handle.net/2077/41848>

# SAMMANFATTNING PÅ SVENSKA

Mer än 50% av våra immunceller finns i tarmen. Tarmslemhinnan, som utgör en viktig barriär mot vår omgivning och som skyddar kroppen från skadliga organismer, innehåller s.k. intraepiteliala T lymfocyter (IELs). Dessa lokala immunceller har en unik sammansättning av  $\alpha\beta$  TCR och  $\gamma\delta$  TCR T celler som skiljer sig från kroppens övriga T lymfocyter och är viktiga för igenkänning av stressade och infekterade celler samt för reglering av inflammation i tarmen. Förståelsen kring funktionen av IELs samt konsekvensen av deras interaktion med andra celler i tarmslemhinnan, framför allt epitelceller som de är i direkt kontakt med, är dock fortfarande begränsad. Syftet med projektet var att kartlägga hur Butyrophilin (Btn) och Btn-like (Btl) molekyler medverkar vid kommunikationen mellan epitelceller och intestinala IELs och därmed karaktärisera deras roll vid regleringen av tarmens immunsvaret. Btn och Btl proteiner har de senaste åren uppmärksammats som nya regulatorer av immunförsvaret och har visat sig kunna reglera T lymfocyter och även vara associerade med inflammatoriska sjukdomar och cancer. Vi har visat att funktionen av intestinala IELs, och därmed också immunresponsen i tarmen, kan moduleras av Btl proteiner som uttrycks av tarmens epitelceller, och att interaktionen mellan Btl och IEL i tarmslemhinnan leder till proliferation och aktivering av IELs. Detta pekar på att Btl proteinerna är inblandade i upprätthållande av IEL poolen i tarmen. Vi har vidare identifierat nya biologiska proteinkomplex i tarmepitelet som är uppbyggda av olika Btl proteiner, och visat att dessa komplex ökar proliferationen av en specifik IEL population som uttrycker V $\gamma$ 7V $\delta$ 4 TCR. Eftersom  $\gamma\delta$  T celler är viktiga för upprätthållande av homeostasen i tarmen, tex genom att medverka vid nygenerering av epitelceller, samt kan känna igen och eliminera stressade epitelceller, är det viktigt att veta hur dessa T celler regleras. Vi har även tittat på hur de lokala Btl proteinerna regleras i den neonatala tarmen. Våra data demonstrerar att uttrycket av de vävnadsspecifika Btl proteinerna är fördröjt i tarmen de första veckorna efter födseln och att proteinerna inte är detekterbara i tarmslemhinnan före 3 veckors ålder i mus. Detta kan ha konsekvenser för expansionen av IEL populationen i den neonatala tarmen och därmed också för tarmens immunrespons tidigt i livet. För att öka förståelsen för Btn och Btl genernas funktion vid tarmrelaterade sjukdomar har vi karaktäriserat uttryck av humana och mus Btn och Btl gener vid inflammation och cancer i tarmen. Våra resultat demonstrerar att uttrycket av flera av dessa gener är förändrat vid dessa sjukdomar och visar på en

association mellan Btn och Btnl gener och ulcerös kolit och colon cancer. Sammanfattningsvis har vår forskning visat att Btn och Btnl proteiner kan reglera funktionen av intestinala T lymfocyter och därmed immunresponen i tarmslemhinnan, samt att Btn och Btnl gener är associerade med tarmrelaterade sjukdomar. En fortsatt kartläggning av Btnl proteinernas betydelse för immunregleringen i tarmslemhinnan är viktig för att ytterligare öka förståelsen för hur immunsystemet regleras i frisk och inflammerad/infekterad tarm.



# LIST OF PAPERS

This thesis is based on the following studies, referred to in the text by their Roman numerals.

- I. Cristina Lebrero-Fernández, Joakim H. Bergström\*, Thaher Pelaseyed\* and Anna Bas-Forsberg.  
**Murine Butyrophilin-like 1 and Btl6 form heteromeric complexes in small intestinal epithelial cells and promote proliferation of local T lymphocytes.**  
*Front Immunol.* 2016 Jan 19; 7: 1. doi: 10.3389/fimmu.2016.00001
- II. Cristina Lebrero-Fernández and Anna Bas-Forsberg.  
**The ontogeny of Butyrophilin-like (Btl) 1 and Btl6 in murine small intestine.**  
*Submitted for publication*
- III. Cristina Lebrero-Fernández, Thaher Pelaseyed and Anna Bas-Forsberg.  
**Butyrophilin-like (Btl) 4 forms heteromeric intra-family complexes and its expression is delayed in the intestine during ontogeny.**  
*Manuscript*
- IV. Cristina Lebrero-Fernández, Ulf Alexander Wenzel, Paulina Akeus, Ying Wang, Hans Strid, Magnus Simrén, Bengt Gustavsson, Lars G. Börjesson, Susanna L. Cardell, Lena Öhman\*, Marianne Quiding-Järbrink\* and Anna Bas-Forsberg.  
**Altered expression of Butyrophilin (BTN) and BTN-like (BTNL) genes in intestinal inflammation and colon cancer.**  
*Immun Inflamm Dis.* 2016 April 1. doi: 10.1002/iid3.105

\* The authors contributed equally to this study

*Reprints were made according to the journal requirements*



# TABLE OF CONTENTS

ABSTRACT.....	5
SAMMANFATTNING PÅ SVENSKA.....	7
LIST OF PAPERS.....	9
TABLE OF CONTENTS.....	11
ABBREVIATIONS.....	13
1. INTRODUCTION.....	15
1.1 Intraepithelial lymphocytes.....	16
IELs heterogeneity and phenotype.....	16
IELs development and ontogeny.....	17
IELs function.....	18
1.2 Intraepithelial $\gamma\delta$ T cells.....	19
Intraepithelial $\gamma\delta$ T cells during homeostasis.....	21
Cross-talk between intraepithelial $\gamma\delta$ T cells and epithelial cells.....	22
1.3 Butyrophilin and Butyrophilin-like molecules.....	24
Btn and Btl genes belong to the family of co-stimulatory molecules..	24
Butyrophilin and Butyrophilin-like family.....	24
Immunological functions of human BTN and BTNL molecules.....	26
Immunological functions of murine Btn and Btl molecules.....	28
Btn and Btl proteins and their counter-receptors.....	29
2. AIMS.....	31
3. KEY METHODOLOGY.....	33
3.1 Mice.....	33
3.2 Patients and specimen collection.....	33
3.3 Cell lines and generation of transiently and stably transfected cells ...	34
3.4 Generation of polyclonal antibodies.....	35
3.5 Preparation of cell suspensions and cell culture.....	35
3.6 <i>In vitro</i> T cell proliferation assay.....	36
3.7 Flow Cytometry.....	36
3.8 Cytokine Assay.....	37
3.9 Immunofluorescent staining.....	37
3.10 Western Blotting.....	38
3.11 Immunoprecipitation.....	39
3.12 Mass Spectrometry.....	40
3.13 Quantitative real-time PCR.....	40
3.14 Statistical analysis.....	42

4. RESULTS AND DISCUSSION.....	43
4.1. Btl protein expression and the proteins' biological forms (Papers I and III).....	43
4.2. Btl expression in the absence of gut microbiota and in the ontogeny (Papers II and III).....	45
4.3. Immunological role of Btl proteins (Papers I and II).....	46
4.4. Human and murine <i>BTN</i> and <i>BTNL</i> gene expression in normal colon (Paper IV).....	48
4.5. Human <i>BTN</i> and <i>BTNL</i> gene expression in intestinal inflammation and cancer (Paper IV).....	49
4.6. Murine <i>Btl</i> and <i>Btl</i> gene expression in intestinal inflammation and cancer (Paper IV).....	51
5. CONCLUDING REMARKS.....	53
ACKNOWLEDGEMENTS.....	55
REFERENCES.....	59

# ABBREVIATIONS

7AAD	7-aminoactinomycin D
Apc	Adenomatous polyposis coli
APC	Antigen presenting cell
B7-H3	B7 homologue 3
BSA	Bovine serum albumin
BTN	Butyrophilin
BTNL	Butyrophilin-like
CAR	Coxsackie and adenovirus receptor
CCL	CC-chemokine ligand
CCR	CC-chemokine receptor
cDNA	Complementary DNA
CFSE	Carboxyfluorescein diacetate succinimidyl ester
CTLA	Cytotoxic T lymphocyte antigen
CV	Conventional
CXCL	CXC-chemokine ligand
DAPI	4',6'-diamidino-2-phenylindole
DC	Dendritic cell
DETC	Dendritic epidermal T cell
DMEM	Dulbecco's modified essential medium
DN	Double negative
DNA	Deoxyribonucleic acid
DTT	Dithiothreitol
EAE	Experimental autoimmune encephalomyelitis
ELISA	Enzyme-linked immunosorbent assay
ERMAP	Erythroblast membrane associated protein
FasL	Fas ligand
FCS	Fetal calf serum
GF	Germ-free
HEK	Human embryonic kidney
IBD	Inflammatory bowel disease
IBS	Irritable bowel syndrome
ICOS	Inducible co-stimulator
iEC	Intestinal epithelial cell
IEL	Intraepithelial lymphocyte
IF	Immunofluorescence
IFN- $\gamma$	Interferon- $\gamma$
Ig	Immunoglobulin

IGF-1	Insulin-like growth factor-1
IL	Interleukin
ILC	Innate lymphoid cell
iNKT	Invariant natural killer T
IP	Immunoprecipitation
JAML	Junctional adhesion molecule-like
KGF	Keratinocyte growth factor
KLH	Keyhole limpet hemocyanin
LN	Lymph node
LPL	Lamina propria lymphocyte
MAIT	Mucosal-associated invariant T
MHC	Major histocompatibility complex
Min	Multiple intestinal neoplasia
MIP	Macrophage inflammatory protein
MOG	Myelin oligodendrocyte glycoprotein
MS	Multiple sclerosis
MS	Mass spectrometry
Muc	Mucin
MZB	Marginal zone B
NHS	Normal horse serum
NK	Natural killer
pAg	Phosphoantigen
PD-L	Programmed death-ligand
PEI	Polyethylenimine
PI3K	Phosphatidylinositol 3-kinase
qPCR	Quantitative polymerase chain reaction
RAG	Recombination-activating gene
RNA	Ribonucleic acid
SIGN	Specific intercellular adhesion molecule-3-grabbing non-integrin
SNP	Single nucleotide polymorphism
TCR	T cell receptor
TGF- $\beta$	Transforming growth factor- $\beta$
TNF- $\alpha$	Tumor necrosis factor- $\alpha$
Treg	Regulatory T cell
TRIM	Tripartite motif
UC	Ulcerative colitis
VEGF	Vascular endothelial growth factor
WB	Western blotting
WT	Wild-type

# 1. INTRODUCTION

Our body is protected from pathogens and other harmful substances, and the damage they cause, by a variety of effector cells, tissues and molecules that together make up the immune system.


The immune system is traditionally classified in two types: innate and adaptive. The innate immune system is the early line of host defense, and consists of biochemical and cellular mechanisms that are in place even before infection and that provide a rapid non-specific response to invading pathogens. The main components of the innate immune system are physical and chemical barriers, phagocytic cells, dendritic cells (DCs), circulating plasma proteins and innate lymphoid cells (ILCs) like natural killer (NK) cells. In contrast, the response of the adaptive immune system is antigen-specific, being effective only after undergoing clonal expansion and differentiation, which takes several days, and includes memory that makes future responses against a specific antigen more efficient. There are two types of adaptive immune responses: humoral immunity, mediated by antibodies produced by B lymphocytes, and cell-mediated immunity, mediated by T lymphocytes.

Recently, several studies have described the existence of cell populations that possess features of both innate and adaptive immunity, suggesting a concept of a continuum of the immune response. These populations have a restricted repertoire of antigen receptors, they are primarily located in mucosal tissues (particularly near epithelia), and they can be functionally grouped by their capacity to respond to infection during the period between activation of the phagocytic cells of the innate immunity and the T and B cells of the adaptive immunity. These bridge populations are known as innate-like cells and include: gamma delta ( $\gamma\delta$ ) T cells, intraepithelial lymphocytes (IELs), invariant natural killer T (iNKT) cells and mucosal-associated invariant T (MAIT) cells, which express T cell receptors for antigen; and B1-B cells and splenic marginal zone B (MZB) cells, which express B cell receptors for antigen [1, 2].

Although most studies on the biology of T cells focus on systemic T lymphocytes, the recently developed interest for how epithelia, being the primary targets of infection and other forms of damage, may influence lymphocyte activation, regulation and function, has drawn attention to local intraepithelial lymphocytes and their interaction and communication with epithelial cells.

## 1.1 Intraepithelial lymphocytes

IELs are T lymphocytes that reside in the skin and in the mucosal epithelia of the intestine, the biliary tract, the oral cavity, the upper respiratory tract and lungs, and the reproductive tract. IELs represent a significant fraction of the epithelium, with an average of about one IEL per 5-10 epithelial cells in the murine or human small bowel [3]. Intestinal IELs are located intercalated between the epithelial cells (**Figure 1**), and constitute the largest lymphocyte population in the whole body due to the expanded surface of the small intestine epithelium formed by multiple villi and microvilli. The murine skin also harbors an extensive network of IELs, known as dendritic epidermal T cells (DETCs) for their unique dendritic morphology, which do not seem to have exact human counterparts [4, 5].



**Figure 1.** Small intestinal epithelium (modified from reference [6]).

IEL: intraepithelial lymphocyte; LPL: lamina propria lymphocyte.

### IELs heterogeneity and phenotype

Murine and human IELs differ from the systemic T cells in their subset composition. Unlike the spleen, peripheral blood and lymph node T cells that can be subdivided into major histocompatibility complex (MHC) class



II-restricted CD4<sup>+</sup> TCR $\alpha\beta$ <sup>+</sup> T cells and MHC class I-restricted CD8 $\alpha\beta$ <sup>+</sup> TCR $\alpha\beta$ <sup>+</sup> T cells, the IEL population is more heterogeneous and can be classified into two major subpopulations based on the expression of the T cell receptors (TCRs) and co-receptors: the first group, called conventional or type a IELs and more recently named as induced IELs, consists of conventional CD4<sup>+</sup> and CD8 $\alpha\beta$ <sup>+</sup> TCR $\alpha\beta$ <sup>+</sup> T cells, while the second subset, referred to as unconventional, type b or natural IELs, is made up of CD8 $\alpha\alpha$ <sup>+</sup> TCR $\alpha\beta$ <sup>+</sup>, CD4<sup>-</sup> and CD8<sup>-</sup> (double negative, DN) TCR $\gamma\delta$ <sup>+</sup>, and CD8 $\alpha\alpha$ <sup>+</sup> TCR $\gamma\delta$ <sup>+</sup> IELs [7, 8]. These IEL types are found in both humans and mice, however, CD8 $\alpha\alpha$ <sup>+</sup> TCR $\alpha\beta$ <sup>+</sup> IELs are present in human fetal intestine but have not been formally identified in adults [9, 10]. In contrast to the small bowel, the murine and human large intestine, which harbors the greatest microbial antigen load, is mainly composed by conventional IELs [7], and the murine skin DETCs are DN TCR $\gamma\delta$ <sup>+</sup>, which belong to the unconventional IEL group [11, 12].

Unconventional IELs typically express a CD3 complex composed of CD3 $\zeta$ -Fc $\epsilon$ RI $\gamma$  heterodimers or Fc $\epsilon$ RI $\gamma$ -Fc $\epsilon$ RI $\gamma$  homodimers instead of CD3 $\zeta$ -CD3 $\zeta$  homodimers, express by conventional IELs [13].

Furthermore, intestinal IELs are CD69<sup>+</sup> and CD44<sup>+</sup>, but they do not show markers of recently activated cells such as CD25. They are heterogeneous in terms of the expression of conventional T cell markers such as CD2, CD5 and CD28. In contrast to the unconventional IELs, conventional IELs express a typical phenotype of memory T cells namely CD2<sup>+</sup>CD5<sup>+</sup>CD28<sup>-</sup>cytotoxic T lymphocyte antigen (CTLA)-4<sup>+</sup>Thy1<sup>+</sup>LyC6<sup>+</sup> [14, 15].

Thus, IELs appear as activated effector cells but require additional activation to manifest a full functional potential, which suggests that the IEL compartment has an “activate yet resting” constitutive state [14, 16].

## **IELs development and ontogeny**

IEL subsets are progeny of precursor cells located in the bone marrow or in the fetal liver, however, their development and maturation is not uniform. Conventional IELs are restricted to MHC and are thymus derived as they are absent in athymic mice [17, 18]. They acquire an activated phenotype in response to antigens in peripheral lymphoid tissue and migrate into mucosal epithelia, presumably awaiting a second exposure to antigen, akin to memory effector cells in other tissues. Unconventional IELs can be either thymus-independent – they are detected in athymic mice [17-22] and they are

believed to develop in gut-associated cryptopatches located in crypt lamina propria [23], or thymus-dependent like murine DETCs and genital tract TCR $\gamma\delta^+$  IELs, which are primarily generated in the fetal thymus [24]. Unconventional IELs are not dependent on classical MHC molecules.

Intestinal IELs constitutively express CD103 (also known as  $\alpha E\beta 7$  integrin) and CC-chemokine receptor 9 (CCR9), which interact with E-cadherin and CC-chemokine ligand 25 (CCL25), respectively, on intestinal epithelial cells, resulting in gut-homing [25].

Ontogeny studies of intestinal IELs demonstrate that newborn rodents have resident IELs in the small bowel, being mainly TCR $\gamma\delta^+$  IELs, and that the population increases until weaning age. By contrast, TCR $\alpha\beta^+$  IELs are infrequent early in life, but expand with age in response to external antigens [26-28]. Moreover, in the absence of microbiota (germ-free mice) and dietary proteins (antigen-free mice), the IEL subsets are notably reduced with the exception of TCR $\gamma\delta^+$  IELs [29, 30].

### **IELs function**

IELs are situated within the epithelium, which not only offers obvious opportunities for direct epithelial cell - T cell interaction, but also an immediate response against pathogenic infection, cell transformation and uncontrolled infiltration by systemic cells in order to preserve the epithelial integrity [7, 8, 12].

IELs exhibit potent cytotoxic capacities mediated by the release of granzyme and perforin located in cytoplasmic granules [31], and by activation-induced expression of Fas ligand (FasL), which induces apoptotic cell death upon ligation with Fas on target cells [16]. IELs additionally produce a variety of chemokines, e.g. macrophage inflammatory protein 1 $\alpha$  (MIP-1 $\alpha$ ) and MIP-1 $\beta$ ; cytokines, such as interferon- $\gamma$  (IFN- $\gamma$ ), tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), transforming growth factor- $\beta$  (TGF- $\beta$ ), interleukin (IL)-2, IL-4, IL-5, IL-6, IL-10, IL-13 or IL-17 [14, 32]; and growth factors [33, 34]. Furthermore, IELs express NK cell receptors and can lyse target cells in a TCR-independent manner [35]. This artillery of effector molecules is essential for the maintenance of the epithelial integrity and the protection from severe infection and inflammation. Indeed, IELs have shown to display protective functions against enteric viral, bacterial or parasitic infection, where they secrete perforins, granzymes, IFN- $\gamma$ , TGF- $\beta$  and TNF- $\alpha$ , which are essential for host immunity to the pathogens [36-40]. IELs can also prevent or reduce the severity of some inflammatory diseases like colitis or celiac disease, by

expressing anti-inflammatory cytokines such as TGF- $\beta$  and IL-10, and keratinocyte growth factors (KGFs), which allow to preserve the epithelium and restore tissue integrity after injury [33, 41, 42]. Moreover, DETCs can express high levels of IFN- $\gamma$  and granzymes, but they also express IL-13, which can regulate B cells [43].

Although IELs show beneficial roles, they can exert uncontrolled cytotoxicity and enhance immune responses, which may initiate or exacerbate inflammatory diseases. Thus, several reports demonstrate a direct correlation between the number of IELs in the intestinal mucosa and disease severity in patients with intestinal inflammatory bowel disease (IBD) [44-46], where these IELs can be responsible for the colitis induction through the secretion of IL-17 [47]. Furthermore, IL-15, which is over-expressed by intestinal epithelial cells from individuals with celiac disease, is known to trigger potent cytotoxic responses by IELs [48].

## 1.2 Intraepithelial $\gamma\delta$ T cells


$\gamma\delta$  T cells, together with  $\alpha\beta$  T cells and B cells, represent the three lymphocyte lineages found in all vertebrates [49]. Similar to B cell receptors and  $\alpha\beta$  T cell receptors, the variable region of the  $\gamma\delta$  TCRs is generated through somatic rearrangement of V (variable), D (diversity) and J (joining) segments, through the activity of the recombination-activating genes encode enzymes, RAG-1 and RAG-2. Structural diversity of  $\gamma\delta$  TCRs depends on combination of different sets of V, D and J segments, and addition or loss of nucleotides in joining sites [50-52]. Some  $\gamma\delta$  T cell subsets in particular tissue locations, such as the skin and the uterine epithelia, have no junctional diversity and thus, they express invariant TCRs with canonical junctional sequences [53]. These invariant  $\gamma\delta$  T cell subsets are derived from fetal  $\gamma\delta$  T cells, unlike peripheral subsets that express more diverse  $\gamma\delta$  TCRs [54].

The antigen-receptor repertoire of human and mouse  $\gamma\delta$  T cells is encoded by  $V\gamma$  and  $V\delta$  genes. The most common  $V\gamma$  chains in mice are:  $V\gamma 1$ ,  $V\gamma 2$ ,  $V\gamma 4$ ,  $V\gamma 5$ ,  $V\gamma 6$  and  $V\gamma 7$ . Invariant  $V\gamma 5V\delta 1$  DETCs and  $V\gamma 6V\delta 1$  T cells are located in the epidermis and in the uterovaginal epithelia, respectively [55].  $\gamma\delta$  T cells predominantly use:  $V\gamma 1$  or  $V\gamma 7$  chains combined with various TCR $\delta$  chains in the gut [56],  $V\gamma 1$  or  $V\gamma 4$  chains in the spleen,  $V\gamma 1$ ,  $V\gamma 4$  or  $V\gamma 6$  chains in the liver, and  $V\gamma 4$  or  $V\gamma 6$  chains in the lung epithelia [52, 57]. In humans, the most prevalent  $V\delta$  chains are:  $V\delta 1$ ,  $V\delta 2$  and  $V\delta 3$ . The best defined are the  $V\gamma 9V\delta 2$  T cells, which reside in the peripheral blood [58] (the

## Introduction

TCR nomenclature is according to Heilig and Tonegawa for mouse  $\gamma\delta$  T cells [59] and Lefranc and Rabbitts for human  $\gamma\delta$  T cells [60]).

In mouse,  $\gamma\delta$  T cells are exported from the fetal thymus to epithelia-rich tissues in programmed waves (**Figure 2**). The first wave of  $\gamma\delta$  T cells populates the epidermis, the second wave homes the epithelia of the reproductive tract and lung, and the third wave colonizes the gut, the spleen and the lymph nodes. After these initial waves,  $\alpha\beta$  T cells predominate, making up more than 95% of the T cells [51, 52, 61].



**Figure 2.** T cell development occurs in waves.

Modified from Janeway et al. Immunobiology. NY: Garland Science; 2001.

LN: lymph node.

In the periphery,  $\gamma\delta$  T cells play an important role in the immunity of a broad range of infectious stresses [62] and in tumor immune surveillance [63].  $\gamma\delta$  T cells directly lyse and eliminate infected or stressed cells through the production of granzymes, and produce a vast variety of cytokines and chemokines to regulate other immune or non-immune cells [64, 65]. Moreover, they also trigger DC maturation [66-68], provide help for B cells and promote the production of immunoglobulin E (IgE) [69, 70], and

present antigens for  $\alpha\beta$  T cell priming [71-73]. Furthermore,  $\gamma\delta$  T cells are implicated in protection against cancer, killing tumor cells and secreting potent anti-tumor cytokines such as IFN- $\gamma$  [74-78]. However, they are also involved in tumor promotion. Thus,  $\gamma\delta$  T cells producing IL-17 [79, 80], IL-4 [81], IL-10 and TGF- $\beta$  suppress anti-tumor immune responses by inhibiting effector functions of  $\gamma\delta$  T cells and CD4<sup>+</sup> and CD8<sup>+</sup>  $\alpha\beta$  T cells [63, 82, 83], and by recruiting immunosuppressive myeloid cells that promote angiogenesis, tumor cell growth and regulatory T cells (Treg) differentiation [84, 85].

Although  $\gamma\delta$  T cells can be found in the periphery, they mainly reside in epithelial tissues being part of the IEL compartment. Intraepithelial  $\gamma\delta$  T cells, also known as  $\gamma\delta$  IELs, play unique roles in homeostasis and disease. They participate in tissue repair regulating epithelial cell turnover and differentiation, and producing epithelial growth factors, cytokines and chemokines [33, 34, 86]. At the same time, they are involved in protection from malignancy, recruiting inflammatory cells to the site of damage and killing diseased epithelial cells through their high cytolytic potential [87-89]. Several studies have reported deficiency in wound healing [55, 90], tumor rejection [89], recovery from colitis [33], lung injury [91] and homeostatic regulation of the epithelia [92] in the absence of  $\gamma\delta$  IELs ( $\gamma\delta$  TCR<sup>-/-</sup> mice).

### **Intraepithelial $\gamma\delta$ T cells during homeostasis**

Intestinal and skin intraepithelial  $\gamma\delta$  T cells have been shown to be essential in tissue homeostasis and repair. In the gut, intraepithelial  $\gamma\delta$  T cells regulate the regeneration and differentiation of intestinal epithelial cells (iECs), controlling the epithelial cell growth and differentiation [86, 93]. In the skin, DETCs contribute to wound healing through secretion of distinct growth factors including KGFs and insulin-like growth factor-1 (IGF-1) [34, 92, 94, 95]. IGF-1 is involved in reverse the epidermal apoptosis and it is constitutively expressed by DETCs [92]. Furthermore, DETCs express chemokines such as MIP-1 $\alpha$ , MIP-1 $\beta$ , RANTES and lymphotactin, to recruit specialized inflammatory cells, and cytokines including IL-2, IFN- $\gamma$ , TNF- $\alpha$  and IL-17 upon activation [96, 97]. This suggests that DETCs not only regulate epidermal homeostasis, but also immune responses during stress or damage.

The cytokines IL-7 and IL-15 are essential for development, localization and survival of  $\gamma\delta$  T cells, as well as for their homeostasis [98-101]. The development and survival of the epidermal  $\gamma\delta$  IELs (DETCs) is dependent

on IL-7, but not IL-15 [102], whereas the generation and maintenance of intestinal intraepithelial  $\gamma\delta$  T cells relies on the presence of both IL-7 and IL-15 [103]. Furthermore, normal  $\gamma\delta$  IEL development is also dependent on the development of conventional  $\alpha\beta$  IELs [104].

### **Cross-talk between intraepithelial $\gamma\delta$ T cells and epithelial cells**

In some epithelial tissues, like the murine skin, intraepithelial  $\gamma\delta$  T cells comprise the main T cell population, whereas in other epithelial sites, such as the intestinal epithelium, they coexist with  $\alpha\beta$  T cells [24]. Intraepithelial  $\gamma\delta$  T cells are in close contact with the neighboring epithelial cells, and although the communication between them is considered as essential, few molecular inter-cell interactions have been identified [105, 106]. The best characterized examples of epithelial cell - IEL interaction are:

#### **- NKG2D**

The activating receptor, NKG2D, is a transmembrane protein that belongs to the family of the C-type lectin-like receptors, which is expressed as a homodimer on NK,  $\gamma\delta$  and CD8<sup>+</sup> T cells [107, 108]. In humans, NKG2D is engaged by MICA and MICB, as well as by members of the ULBP family [107, 109], and in mice, by Rae-1, H60 and Mult1 [107, 109]. All NKG2D ligands are homologous to MHC molecules, and they are absent or present at low levels under homeostatic conditions, but are up-regulated by infected, transformed and stressed epithelial cells [108].

NKG2D has been shown to provide important co-stimulatory signals for intraepithelial  $\gamma\delta$  T cell activation and function in damaged intestinal and skin tissues: in humans, intestinal intraepithelial  $\gamma\delta$  T cells expressing the V $\delta$ 1  $\gamma\delta$  TCR can recognize the NKG2D ligands MICA and MICB, and may serve as an immune surveillance mechanism or may be involved in the maintenance of epithelial homeostasis [87, 88, 110], and in mice, the engagement of NKG2D with its ligands activates DETCs [89, 111-113].

#### **- JAML**

JAML, or Junctional Adhesion Molecule-Like, is a transmembrane glycoprotein expressed on neutrophils, monocytes and memory T cells [114]. Low levels of JAML were also found on mouse epidermal  $\gamma\delta$  IELs under steady-state conditions and up-regulated upon activation [115]. JAML is

engaged by the Coxsackie and Adenovirus receptor (CAR), expressed on keratinocytes (epidermal epithelial cells) and intestinal epithelial cells [116].

Binding of JAML to its ligand provides co-stimulation that results in proliferation, through the recruitment of phosphatidylinositol 3-kinase (PI3K), and activation of DETCs, as well as in production of cytokines such as IL-2, IFN- $\gamma$  and TNF- $\alpha$ , and expression of KGF-1 by DETCs. Thus, the cross-talk between JAML and CAR is a crucial component in epidermal wound repair [115, 117].

#### - **CD100**

CD100, also known as Semaphorin 4D, is a member of the semaphorin family, which is expressed on B and T cells, including intraepithelial  $\gamma\delta$  T cells [118-120]. Engagement between CD100 and one of its ligands, plexin B2, is critical for activation of intraepithelial  $\gamma\delta$  T cells [120]. Interaction between CD100 on DETCs and plexin B2 on keratinocytes plays an important role in response to keratinocyte damage in the epidermis [120]. In colon, interaction between CD100 on intestinal  $\gamma\delta$  IELs and plexin B2 on epithelial cells is vital for mediating healing of the colon epithelium during colitis [121]. Thus, the cross-talk between CD100 and plexin B2 is a key component in the regulation of wound healing and inflammation.

#### - **Skint-1**

Skint-1 is a transmembrane protein that belongs to the Skint Ig superfamily, which is expressed by epithelial cells in the thymus and the skin [122]. Skint-1 determines the repertoire of the epidermal IEL, being essential for the selection of the murine V $\gamma$ 5V $\delta$ 1 intra-epidermal T cell compartment [122-124]. Furthermore, it has been described that only upon engagement by Skint1, V $\gamma$ 5V $\delta$ 1 DETCs are able to express IFN- $\gamma$ , suggesting that this interaction is vital for the maturation of DETCs [125].

Butyrophilin (Btn) and Butyrophilin-like (Btnl) gene family members have structural relatedness to Skint-1 and are one of the closest relatives outside the Skint family [122, 126]. Btn and Btnl proteins have over the past decade emerged as essential regulators of T cell functions, both in periphery and locally in the tissue [126-130].

## 1.3 Butyrophilin and Butyrophilin-like molecules

### **Btn and Btl genes belong to the family of co-stimulatory molecules**

T cell activation requires two signals. The first signal is the interaction between the peptide-antigen-MHC present on the antigen presenting cell (APC) and the T cell receptor. A second signal, known as co-stimulation, which is crucial to achieve full T cell activation or tolerance, is provided by the interaction between co-stimulatory or co-inhibitory molecules, expressed on APC, and the T cell [131].

One of the best characterized families of co-stimulatory molecules is the B7 superfamily, which has a pivotal role in the regulation of T cell responses. This family includes positive co-stimulatory molecules such as B7-1 (CD80 in humans), B7-2 (CD86 in humans) and inducible co-stimulator ligand (ICOS-L), and negative co-stimulatory molecules such as programmed death-ligand 1 (PD-L1), PD-L2, B7 homologue 3 (B7-H3) and B7-H4, expressed by APCs [132, 133].

B7-1 and B7-2 can bind to CD28 or CTLA-4, which are expressed on the T cell surface, delivering activatory or inhibitory signals to T cells, respectively. In addition, ICOS-L interacts with ICOS providing activatory signals, and PD-L1/PD-L2 and B7-H3/B7-H4 bind to PD-1 and B7-H3/B7-H4 T cell expressed-receptors, respectively, inducing inhibitory responses that are crucial for immune tolerance [132, 133].

Btn and Btl molecules share strong homologies with the B7 family and independent studies over the past 10 years have demonstrated immunological functions for several of the Btn and Btl family members [126-130, 133, 134].

### **Butyrophilin and Butyrophilin-like family**

The *BTN* and *BTNL* genes are clustered on human chromosomes 5 and 6, and on mouse chromosomes 11, 13 and 17. Several are located within the MHC-locus and are conserved in mice and humans [135, 136].


To date, 11 members (7 *BTN* and 4 *BTNL*) have been identified in humans. The *BTN* molecules are divided in three phylogenetic associated subfamilies: *BTN1*, *BTN2* and *BTN3*. The *BTN1* group is composed only of *BTN1A1*, while the *BTN2* and *BTN3* subfamilies contain three molecules *BTN2A1*,



BTN2A2 and BTN2A3 (pseudogene), and BTN3A1, BTN3A2 and BTN3A3, respectively. The 4 BTNL molecules found in humans are BTNL2, BTNL3, BTNL8 and BTNL9. In mouse, 9 members (2 Btn and 7 Btl) have been described. The Btn molecules include Btn1a1 and Btn2a2, whereas the Btl molecules include Btl1, Btl2, Btl4, Btl5 (pseudogene), Btl6, Btl7 (pseudogene) and Btl9. Among all these members, only BTN1A1, BTN2A2, BTNL2 and BTNL9 are clear orthologues between human and mouse [126, 127, 130].

In addition to the BTNL molecules mentioned above, there are other Butyrophilin-like molecules described. One of them is BTNL10 (BTN4), however, it appears unclear if it produces a full-length transcript [129]. Others have received non-BTNL names: erythroblast membrane associated protein (ERMAP or BTN5) and myelin oligodendrocyte glycoprotein (MOG or BTNL11), both found in human and mouse [129]. While ERMAP is involved in the development of erythroid cells [137, 138], MOG is a glycoprotein involved in the myelination of nerves in the central nervous system and has been linked to immune-related functions [139, 140].

Like the B7 family, the structure of the Btn and Btl family members consists of two extracellular Ig-like domains (IgV and IgC), a transmembrane domain and a cytoplasmic domain. Additionally, most of the family members, except for Btl2, BTN3A2 and MOG, contain a B30.2 intracellular domain (**Figure 3**) [126-130, 136].



**Figure 3.** Structural organization of the Btn and Btl family members, which are structurally related to the Skint and B7 families.

The B30.2/SPRY domain, present in several protein families, covers a wide range of functions. Proteins with B30.2/SPRY domain are involved in RNA metabolism (DDX1, hnRNPs) [141], intracellular calcium release (RyR receptors) [142], regulatory and developmental processes (HERC1, Ash2) [143, 144], and regulation of cytokine signaling (SOCS) [145]. A recent evolutionary adaptation, comprising the combination of SPRY and PRY to produce B30.2 domain, is found in Btn/Btnl and tripartite motif (TRIM) molecules [146, 147]. The members of the TRIM family have a variety of functions, such as viral restriction factors (TRIM5 $\alpha$ ) and immune signaling (TRIM21), in which the B30.2 domain appears to be involved in multimerization and binding to ligands [148-150].

Btn and Btnl molecules are expressed at the RNA level in a broad spectrum across human and mouse tissues [126, 128]. Whereas some members are highly restricted to a specific tissue, such as murine *Btnl4* and *Btnl6*, which are limited to intestinal epithelial cells [151], others are widely expressed in lymphoid and non-lymphoid tissues, e.g. *BTN2A1* [152] and *Btn2a2* [153]. Moreover, the transcripts' expression is not always reflected at the protein level, for example, while *Btn1a1* transcripts are broadly detected, Btn1a1 protein is only found in lactating mammary tissue and in thymic stroma [153].

### **Immunological functions of human BTN and BTNL molecules**

Over the recent years, several human BTN and BTNL members have been genetically associated with various immunological diseases. Thus, polymorphisms in the human *BTNL2* have been linked to a growing number of inflammatory disorders, all of which are characterized by inappropriate T cell activation. Thus, single nucleotide polymorphisms (SNPs) in *BTNL2* have been reported to be associated with the following diseases: sarcoidosis [154-163], ulcerative colitis (UC) [164-166], rheumatoid arthritis [167, 168], spontaneous inclusion body myositis [169], systemic lupus erythematosus [167], type I diabetes [167], tuberculosis [166, 170, 171], leprosy [166] and antigen-specific IgE responsiveness [172]. As these diseases are defined by improper T cell activation, the genetic linkage between Btn and Btnl genes and the inflammatory disorders suggests the family's implication in T cell regulation.

Several studies have additionally identified an association between BTN and BTNL members with cancer. Thus, *BTNL2* has been associated with

increased susceptibility to prostate cancer [173] and **BTN3** with ovarian cancer [174-176]. Furthermore, **BTN3A2** has been linked to type I diabetes [177], and **BTN2A1** to metabolic syndrome [178], myocardial infarction through an effect of dyslipidemia [178-182] and hypertension [183].

In addition, several human BTN and BTNL members have been reported to possess immunomodulatory potential by controlling the biological activity of immune cells, mainly peripheral T cells.

Studies on human **MOG (BTNL11)** have shown that the interaction of MOG with dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN), expressed on brain microglia and dendritic cells, is involved in the control of immune homeostasis in the healthy human brain [184]. Moreover, binding of **BTN2A1** to the lectin DC-SIGN was reported to modulate immature monocyte-derived dendritic cells. However, this binding required high mannose glycosylation of BTN2A1, glycosylation typical of transformed cells, suggesting that BTN2A1 could have a role in immune surveillance of tumors [152].

The **BTN3** (also known as CD277) subfamily, which is expressed by most human immune cell subsets, including T cells, B cells, monocytes, dendritic cells and NK cells [185], has been largely studied. Many different functions have been attributed to the BTN3 members, including modulation of T cell function, immune evasion and antigen presentation [128]. Use of distinct anti-BTN3 monoclonal antibodies for elucidating the role of BTN3 on the regulation of T cells has led to different biological outcomes. Whereas 232.5 antibody, which binds and phosphorylates BTN3 on the T cell surface [186], and 103.2 antibody, which sterically blocks the association of proteins engaged by BTN3 during activation [187], inhibited T cell activation; 20.1 antibody, which binds to a different epitope on BTN3 that results in cross-linking of the BTN3 molecules [187, 188], triggered T cell activation. Binding of distinct antibodies leads to changes in the organization of BTN3 molecules on the cell surface and thus, it is likely that these structural and biophysical differences contribute to the different functional outputs of these antibodies. Furthermore, it has been reported that BTN3 is highly up-regulated in tumor cells in ovarian cancer by soluble mediators present in the tumor microenvironment, including CCL3 and vascular endothelial growth factor (VEGF), and that its engagement on the surface of activated T cells attenuated anti-tumor T cell responses [174]. Additionally, recent studies have demonstrated that **BTN3A1** can present phosphoantigens (pAgs) to V $\gamma$ 9V $\delta$ 2 T cells, predominantly located in the human blood, and hence, can

act as an antigen-presenting molecule to activate unconventional T cells, which will be recruited to the sites of infection developing their killing potential [188-193].

Although most data suggest an inhibitory role of BTN and BTNL molecules in immune cell activation, there are recent data showing that Butyrophilin-like molecules can also trigger T cell activation. Studies have suggested that **BTNL8**, expressed in neutrophils, binds to resting but not activated T cells, and that the addition of BTNL8-Fc fusion protein to T cell cultures co-stimulated proliferation and cytokine production *in vitro* [194].

### **Immunological functions of murine Btn and Btl molecules**

The Btn and Btl family members are characterized by their similarity to the first identified Btn protein, **Btn1a1**, which is involved in the regulation of milk lipid droplets production and secretion during lactation [195, 196]. Recent studies have, however, identified novel immunoregulatory functions for Btn1a1. Thus, Btn1a1, expressed in mammary glands, thymic stromal cells and B cells, has also been reported to be capable of inhibiting T cell responses in *in vitro* assays using Btn1a1-Fc fusion protein [153].

Immunological functions have additionally been identified for several of the other family members. Different mouse studies have documented the influence of **Mog (Btl11)** in the neuroinflammatory diseases multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE) [197, 198]. *Mog*<sup>-/-</sup> mice revealed that the lack of immune tolerance to Mog in wild-type mice is responsible of the Mog-induced EAE [199]. Furthermore, it was detected that treatment of mice suffering from EAE with Btn1a1 protein can suppress the disease progression due to molecular mimicry and antibody cross-reactivity between Mog and Btn1a1 [200-202].

Studies on mouse **Btn2a2** have demonstrated similar inhibitory effects as for Btn1a1 [153]. Btn2a2 is expressed on thymic epithelial cells, as well as on dendritic cells, monocytes and B cells [153]. Binding of Btn2a2-Fc to activated T cells inhibited TCR activation and induced *de novo* expression of Foxp3 in T cells [153, 203]. Moreover, *Btn2a2*<sup>-/-</sup> mice revealed enhanced T cell responses, potentiated anti-tumor responses, and exacerbated Mog-induced EAE, increasing the evidence of a negative immunomodulatory role of Btn2a2 [204].

Much of attention has been focused on **Btnl2**, due to the genetically association of human *BTNL2* polymorphisms with several inflammatory disorders [154-172]. Btnl2 is largely expressed on intestinal epithelial cells, dendritic cells and macrophages, in mucosal and lymphoid tissues [205, 206]. Several *in vitro* studies revealed that Btnl2-Fc fusion protein can inhibit T cell proliferation and cytokine production in response to a TCR activating signal in peripheral T cells [205, 206]. Furthermore, Btnl2-Fc was demonstrated to promote expression of Foxp3, a transcription factor necessary for the development and function of Tregs, and thus, to be able to promote the development of regulatory T lymphocytes [207]. Additionally, over-expression of *Btnl2* gene was reported in *Mdr1 $\alpha$ <sup>-/-</sup>* mice, a mouse model of IBD [206], suggesting that Btnl2 is involved in down-modulation of immune responses and thus, in the control of inflammation.

Characterization of **Btnl1** expression demonstrated RNA and protein expression limited to intestinal epithelial cells, but no expression in intestinal lymphoid cells such as IELs or lamina propria lymphocytes (LPLs) [151]. Although a study by another group reported a broader RNA expression, presenting transcripts in a broad spectrum of lymphoid and non-lymphoid tissues, and in CD8<sup>+</sup> T cells, B cells, DCs and macrophages, the expression was not confirmed on the protein level [208]. Characterization of Btnl1 function demonstrated the ability of Btnl1 to inhibit the effects of T cells. Studies on peripheral T lymphocytes showed that Btnl1-Fc fusion protein inhibited T cell proliferation via cell cycle arrest and IL-2 production, and that mouse treatment with anti-Btnl1 antibodies enhanced T cell immune responses and exacerbated both Mog-induced EAE and allergic asthma [208]. Another study investigating local effects of Btnl1 in tissue demonstrated an effect of Btnl1 in modulation of IEL - epithelial cell interactions in the murine small intestinal mucosa. Epithelial cell expression of Btnl1 was involved in attenuating the ability of these cells to produce pro-inflammatory cytokines and chemokines of the NF $\kappa$ B pathway, such as IL-6, CXC-chemokine ligand 1 (CXCL1) and MIP-1 $\beta$  (CCL4), in response to activated TCR $\alpha\beta$ <sup>+</sup> and TCR $\gamma\delta$ <sup>+</sup> IELs [151].

## **Btn and Btnl proteins and their counter-receptors**

Butyrophilin and Butyrophilin-like proteins mediate complex interactions between different cell types, acting through yet unidentified counter-receptors. The similarity of the domain organization in the Btn/Btnl family to that of the B7 family, together with the observation that Btn-Fc and Btnl-Fc fusion proteins bind to a variety of immune cells (whereas BTN3

members, Btn1, Btn2, Btn9, Btn1a1 and Btn2a2 bind to activated T cells [134, 153, 205, 208], and BTNL8 to resting T cells [194], Btn1, Btn2 and Btn9 also interact with B cells, dendritic cells and macrophages [205, 208]), suggested that they may share binding interactions and partners with the B7 family. This notwithstanding, several studies have shown that Btn-Fc and Btnl-Fc fusion proteins do not interact with known B7 family receptors [134, 153, 194, 206, 208].

Only one binding partner has been identified so far for the Btn/Btnl family. DC-SIGN, expressed by monocytes and dendritic cells, has been shown to interact with the human MOG and BTN2A1 proteins [152, 184].

Also of relevance in this regard is the B30.2 protein domain, which has attracted increasing attention by its possible involvement in T cell interaction [189, 192, 209]. Although the interaction between BTN3A1 and V $\gamma$ 9V $\delta$ 2 T cells is not conclusively established, two major hypotheses have been presented. One suggests a direct binding of pAg to the external IgV domain of BTN3A1, conferring the ability of BTN3A1 to present pAgs on the cell surface to V $\gamma$ 9V $\delta$ 2 T cells [189], whereas the other suggests an indirect pAg presentation, where pAg binds to the intracellular B30.2 domain of BTN3A1, altering the conformation of the extracellular BTN3A1 and thus, driving the activation of V $\gamma$ 9V $\delta$ 2 T cells [192, 210]. However, if the BTN3A1 is the ligand for the  $\gamma\delta$  T cells itself or if it requires other molecules for TCR engagement, remains unknown.

Taken together, multiple data demonstrate a role of the Btn and Btnl molecules in driving modulation of the immune responses. Much of attention has been focused on the implication of the Btn and Btnl molecules in immune responses in the periphery, however, assessing their role in the local tissues is equally important for a complete understanding of their biological effects. Furthermore, the identification of the counter-receptors for Btn and Btnl molecules is also critical for a full insight into the family's immunomodulatory functions.

In conclusion, further and more detailed studies to decipher a comprehensive view of the role of Btn and Btnl molecules are essential to, in the longer run, use them as potential targets for diagnosis and therapeutics.

## 2. AIMS

The overall aim of this thesis was to explore the role of the Butyrophilin-like molecules in regulating local T cell mediated immune responses in the gut. The characterization of novel determinants controlling the function of IELs, as well as the identification and exploration of novel IEL – epithelial cell interaction pathways, provides new insights into regulation of T cell mediated immune responses in the intestinal mucosa and thus, into the immune activation and also immune dysregulation in a variety of physiopathological contexts associated with intestinal inflammation and carcinogenic stress.

The specific aims were:

- To further characterize the Btl1, -4 and -6 molecules, defining their protein expression pattern and identifying their biological form.
- To investigate the ability of the gut resident Btl proteins to regulate intestinal IELs.
- To define how the expression of the Btl molecules is regulated in the small intestine during ontogeny and in the absence of gut colonization.
- To determine how *BTN* and *BTNL* genes are regulated in intestinal inflammation and cancer.





## 3. KEY METHODOLOGY

This section provides a general description of the main experimental procedures used in this thesis work. More detailed protocols can be found in the Materials and Methods section of Papers I-IV.

### 3.1 Mice

Mice used in this thesis included common wild-type (WT) strains, i.e. C57BL/6 and C3H/HeN, germ-free (GF) mice and knock-out strains, i.e. *Muc2*<sup>-/-</sup> and *Apc*<sup>Min/+</sup>.

Mouse models of spontaneous colitis (*Muc2*<sup>-/-</sup>) and intestinal tumorigenesis (*Apc*<sup>Min/+</sup>) were used in **paper IV**. *Muc2*<sup>-/-</sup> mice constitute a relevant animal model to study inflammatory bowel diseases. In mouse colon, bacteria are separated from the epithelial cells by the inner mucus layer formed by Muc2 mucin [211]. *Muc2* deficient mice lack secreted mucus, which allows bacteria to penetrate and reach the epithelium, leading to inflammation of the colon and development of spontaneous colitis. Likewise, humans with active ulcerative colitis have an inner mucus layer that is penetrable [212, 213]. *Apc*<sup>Min/+</sup> mice constitute a powerful animal model of intestinal carcinogenesis in humans. Min (multiple intestinal neoplasia) is a mutant allele of the murine *Apc* (adenomatous polyposis coli) tumor suppressor gene, encoding a non-sense mutation. Like humans with germline mutations in *APC*, *Apc*<sup>Min/+</sup> mice are predisposed to intestinal adenoma formation [214, 215].

C57BL/6 and C3H/HeN mice (**paper I**) were purchased from Harlan Laboratories (Netherlands) and Janvier Labs (France), respectively. GF (**paper II**) and conventional (CV) C57BL/6 mice (**papers II and III**), and *Muc2*<sup>-/-</sup> and *Apc*<sup>Min/+</sup> mice (**paper IV**), all on the C57BL/6 background, were bred in the Laboratory of Experimental Biomedicine (EBM), Gothenburg University (Gothenburg, Sweden). All animals were housed at EBM, University of Gothenburg. Protocols were approved by the government animal ethics committee (permits no. 335-2012, 310-2010, 280-2012 and 110-2013), and institutional animal care and use guidelines were followed.

### 3.2 Patients and specimen collection

Colon biopsies from 16 patients with UC, 8 patients with irritable bowel syndrome (IBS) and 17 patients with colon cancer were included in **paper IV**. Parameters analyzed in UC and IBS patients were compared to 18

healthy subjects who served as controls in the study, while parameters analyzed in the tumor of colon cancer patients were compared to unaffected mucosa from the same individuals. Patients were recruited at Sahlgrenska University Hospital, Gothenburg, and Södra Älvsborgs Hospital, Borås, Sweden. The study was performed according to the Declaration of Helsinki and approved by the Regional Ethical Review Board in Gothenburg. All volunteers gave a written informed consent before participation.

Intestinal biopsies were collected and placed immediately in RNAlater (Ambion®) for 24 hours before freezing at -80°C and subsequent RNA extraction.

### **3.3 Cell lines and generation of transiently and stably transfected cells**

HEK 293 cell line, derived from human embryonic kidney cells grown in tissue culture [216], 3T3 fibroblast cell line, derived from murine embryonic tissue [217], and murine intestinal epithelial cell line MODE-K, derived from C3H/He mice [218] were used in **papers I-III**. Cells were maintained at 37°C, 5% CO<sub>2</sub> in Dulbecco's modified essential medium (DMEM; Gibco®, Life Technologies) plus 10% fetal calf serum (FCS; PAA Laboratories), 100 U/ml penicillin, 100 µg/ml streptomycin, 0.292 mg/ml glutamine and 1× non-essential amino acids (Gibco®, Life Technologies).

Cell transfection is a technique commonly used to introduce exogenous DNA to cells. There are two categories: transient transfection, in which the introduced DNA persists in cells for a limited period of time; and stable transfection, in which the cells pass the introduced DNA to their progeny, because the transfected DNA has been incorporated into the genome.

In **papers I and III**, HEK 293 and MODE-K cells were transiently transfected with Btnl1-, Btnl4-, Btnl6-, Btnl4- + Btnl1-, Btnl6- + Btnl1-, Btnl6- + Btnl4-pMX-IRES-GFP or pMX-IRES-GFP (empty vector) using polyethylenimine (PEI; Polysciences) or lipofectamine (Invitrogen™, Life Technologies) according to standard procedures.

In **papers I-III**, MODE-K cells were stably transfected with Btnl1-, Btnl4-, Btnl6-, Btnl6- + Btnl1-pMX-IRES-GFP or pMX-IRES-GFP, by transduction with viral supernatants, and sorted for GFP<sup>hi</sup> cells on a BD FACS Aria™ II cell sorter (BD Bioscience) or an iCyt Synergy™ cell sorter (BioLegend).

Untagged Btl1-pMX-IRES-GFP and N-terminal FLAG-tagged or HA-tagged Btl1-pMX-IRES-GFP constructs were used based on the experiments' requirements.

### 3.4 Generation of polyclonal antibodies

Antibodies are produced by the immune system in response to the presence of a specific antigen. Depending on the method of production, the antibodies can be classified into polyclonal and monoclonal. A polyclonal antibody represents a collection of antibodies from different B cell lineages that recognize multiple epitopes on the same antigen, whereas a monoclonal antibody represents an antibody from a single B cell lineage and therefore only binds to one unique epitope.

Btl1 and Btl6 polyclonal antibodies used in **papers I and II** were made by Moravian-Biotechnology (Brno, Czech Republic), while Btl4 polyclonal antibody used in **paper III** was produced by Agrisera AB (Vännäs, Sweden). A synthetic peptide from the extracellular murine Btl1 or Btl6 protein sequence was conjugated to an immunogenic carrier protein, keyhole limpet hemocyanin (KLH). Before immunization, the recombinant protein derived from the murine Btl4 protein sequence was emulgated in Freund's adjuvant. These constructs were injected into New Zealand White rabbits or "Agrisera crossbreed" rabbits (a crossbreed between New Zealand White and Aries French rabbits), respectively. Pre-immune serum was collected from each rabbit and purified using a protein A or G column to serve as negative control. The immune-sera were collected post-immunization and specific antibodies were isolated from sera components by affinity purification on a specific peptide/protein column. Enzyme-linked immunosorbent assay (ELISA) against the original peptide/protein was performed to test the reactivity of these antibodies.

### 3.5 Preparation of cell suspensions and cell culture

In **papers I-III**, intestinal epithelial cells, intraepithelial lymphocytes and lamina propria lymphocytes were isolated from murine small intestine according to previously described procedures [219-222]. iECs were recovered at the interface between 40% and 20% Percoll (GE Healthcare Bio-sciences AB), and IELs and LPLs were recovered at the interface between 80% and 40% Percoll. Negative and positive selections with anti-CD45 microbeads (Miltenyi Biotec) were performed in some of the

experiments for purification of iECs and IELs or LPLs, respectively, using an auto-MACS separator (Miltenyi Biotec).

The isolated IELs were either analyzed directly or cultured, making use of a long-term culture system for intestinal IELs that permits IELs to be rested and then rapidly re-activated when stimulated via the TCR [222]. IELs were cultured in the presence of 1  $\mu\text{g}/\text{mL}$  anti-CD3 $\epsilon$  (clone 145-2C11, BD Pharmingen) and a cytokine mixture containing IL-2, IL-3, IL-4 and IL-15 for 48 hours, and thereafter transferred to fresh wells and cultured only in the presence of IL-2. Cells were maintained in 96-well round-bottom plates at 37°C and 10% CO<sub>2</sub>. Medium was replaced every 3–4 days.

In **paper I**, splenocytes were obtained from murine spleen and depleted of B cells by negative selection with anti-CD19 microbeads (Miltenyi Biotec) using an auto-MACS separating system (Miltenyi Biotec).

### 3.6 *In vitro* T cell proliferation assay

The proliferation method used in **paper I** relies on the ability of the carboxyfluorescein diacetate succinimidyl ester (CFSE) highly fluorescent dye to penetrate cell membranes and covalently label intracellular molecules. Due to this covalent coupling reaction, the CFSE can be retained within cells for extremely long periods. The progressive halving of CFSE fluorescence within daughter cells following each cell division allows tracing multiple generations by flow cytometry.

MODE-K cells transduced with Btl1-, Btl6- + Btl1-pMX-IRES-GFP or pMX-IRES-GFP were co-cultured with CFSE-labeled IELs in the presence of anti-CD3 (clone 145-2C11, BD Pharmingen), or in the absence of activation with or without IL-2 (10 U/ml; Roche) or IL-15 (50 ng/ml; R&D Systems); or with CFSE-labeled splenocytes in the presence of anti-CD3 (clone 145-2C11, BD Pharmingen) and anti-CD28 (clone 37.51, BD Pharmingen), or in the absence of activation with IL-2 (10 U/ml; Roche). Lymphocytes were left to proliferate, and cell division and activation was monitored after 72 and 96 hours by flow cytometry. Culture supernatants were collected at 96 hours and used for cytokine protein analysis.

### 3.7 Flow Cytometry

Flow cytometry was used in **papers I-III** for analysis of the expression of cell surface and intracellular molecules, allowing identification and quantification of specific cell types in a heterogeneous cell population. Cell

components were fluorescently labeled and then excited by a laser to emit light at varying wavelengths. CellTrace™ CFSE Cell Proliferation Kit (Molecular Probes®, Life Technologies) was used for assessment of lymphocyte proliferation in **paper I**.

Cell surface and intracellular antigen expression was analyzed using the following fluorochrome-conjugated anti-mouse antibodies: anti-FLAG- or anti-HA-APC (PerkinElmer), rabbit polyclonal anti-Btnl1 and pre-immune serum (Moravian-Biotechnology), anti-CD45-Alexa Fluor 700 (30-F11; eBioscience), anti-CD3ε-FITC (145-2C11; BD Pharmingen™), anti-pan TCRγδ-eFluor 450 (eBioGL3; eBioscience), anti-TCRβ-APC or APC-Cy™7 (H57-597; eBioscience), anti-TCR Vγ1.1/Cr4-PE (2.11; BioLegend), anti-TCR Vδ4-eFluor 660 (GL2; eBioscience), anti-TCR Vγ7-biotin (kindly provided by Dr. Pablo Pereira, Institut Pasteur) and anti-CD25-PerCPCy5.5 (PC61.5, eBioscience). APC-conjugated AffiniPure F(ab')<sub>2</sub> fragment donkey anti-rabbit IgG (H+L) (Jackson ImmunoResearch) and streptavidin-APC-Cy™7 (BD Biosciences) were used as secondary antibodies. 7-aminoactinomycin D (7AAD; Sigma-Aldrich) and LIVE/DEAD® Fixable Red Dead Cell Stain (Molecular Probes®, Life Technologies) were used to exclude non-viable cells. For detection of intracellular molecules, cells were permeabilized using a cytofix/cytoperm kit (BD Biosciences). Cell samples were acquired on a BD™ LSR II cytometer, and the analysis was performed using the FlowJo Software version 7.6.5 (BD Bioscience).

### 3.8 Cytokine Assay

Mouse cytokines were measured in supernatants obtained from co-culture experiments in **paper I**, using Mouse Th1/Th2/Th17/Th22 13plex Kit FlowCytomix™ (eBioscience). This method allows the simultaneous detection and quantification of multiple analytes (13 cytokines) in one sample. Samples were acquired on a BD™ LSR II flow cytometer, and data were analyzed using the FlowCytomix™ Pro Software (eBioscience).

### 3.9 Immunofluorescent staining

The immunofluorescence (IF) is a robust tool to detect the location and expression levels of proteins of interest based on the use of fluorochromes bound to antibodies. IF can be used on cells or tissue sections.

In **paper I**, MODE-K cells transiently transfected with FLAG-tagged-Btnl6-, FLAG-tagged-Btnl6- + HA-tagged-Btnl1-pMX-IRES-GFP or pMX-IRES-

GFP, were plated on collagen-coated coverslips. Cells were fixed in 4% paraformaldehyde, and stained with rabbit anti-HA (Sigma-Aldrich) followed by a goat anti-rabbit-Cy5 (Jackson ImmunoResearch) used as secondary antibody, and with anti-FLAG-PE (Prozyme).

In **paper II**, murine small intestinal sections were fixed in methanol-Carnoy's solution and embedded in paraffin. Sectioning was performed using a cryostat. Sections were deparaffinized, antigen-retrieved, stained with rabbit polyclonal anti-Btnl1 or pre-immune serum, and incubated with TRITC-conjugated AffiniPure F(ab')<sub>2</sub> fragment donkey anti-rabbit IgG (H+L) (Jackson ImmunoResearch).

Cells and tissue sections (**papers I and II**) were blocked using 10% normal horse serum (NHS) to prevent unspecific binding of antibodies, and mounted in Prolong<sup>®</sup> Gold antifade reagent containing 4',6'-diamidino-2-phenylindole (DAPI; Molecular Probes<sup>®</sup>, Life Technologies) to visualize nuclei. Images were recorded using the confocal microscope Zeiss LSM700 Inverted available at the Centre of Cellular Imaging at the University of Gothenburg (Gothenburg, Sweden), and analyzed with ZEN lite 2011 microscope software (Carl Zeiss).

### 3.10 Western Blotting

Western blotting (WB) was used in **papers I-III** to detect the presence of Btnl proteins in tissue or cell lysates.

Murine tissues, isolated primary cells or Btnl- transfected MODE-K cells were homogenized in cell lysis buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 1% Triton X-100) containing complete protease inhibitor cocktail tablets (Roche Diagnostics). Lysates were clarified by centrifugation, and total protein quantification was performed with BCA Protein Assay Kit (Pierce), where bovine serum albumin (BSA) is used as protein standard. A specific amount of protein was then denatured in reducing or non-reducing sample buffer (NuPAGE<sup>®</sup> LDS 4x, Novex<sup>®</sup>, Life Technologies; or SDS-PAGE loading buffer) ± 1 M dithiothreitol (DTT) (Sigma-Aldrich) at 95°C for 5 minutes. Incubation of samples with peptide N-glycosidase F (R&D Systems) at 37°C overnight was used in **paper III** for removal of N-glycans. Samples were loaded onto NuPAGE<sup>®</sup> 4-12% Bis-Tris Gels (Novex<sup>®</sup>, Life Technologies) or 6% SDS-PAGE gels. Separated proteins in gels were blotted by wet or semidry transfer to nitrocellulose membranes (Merck Millipore), or Coomassie-stained with Imperial<sup>™</sup> Protein Stain (Thermo Scientific) to visualize the protein bands.

Anti-mouse antibodies used to immunoblot the membranes were: anti-FLAG (Sigma-Aldrich), anti-HA (Sigma-Aldrich), anti-GFP (Sigma-Aldrich), rabbit polyclonal anti-Btnl1, -Btnl4 or -Btnl6 and their pre-immune sera (Moravian-Biotechnology and Agrisera AB), and anti- $\beta$ -actin (Sigma-Aldrich). Specific proteins were then detected using HRP-conjugated goat anti-mouse or anti-rabbit antibodies (Jackson ImmunoResearch). Streptavidin-HRP was used to detect surface proteins which were biotinylated with non-cleavable EZ-link Sulfo-NHS-LC-Biotin (Thermo Scientific) prior to cell lysis. Membranes were developed with Immobilon Western Chemiluminescent HRP Substrate (Merck Millipore), and analyzed with the Fujifilm LAS-4000 Mini luminescence imager.

### 3.11 Immunoprecipitation

Immunoprecipitation (IP) is one of the most widely used methods for purification of proteins from cells or tissue lysates. Proteins are precipitated using specific antibodies and subsequently detected by western blotting or mass spectrometry. When the antibody targets a known protein that is believed to be a member of a complex of proteins, it is possible to pull down the entire complex and thereby identify unknown members of the complex. This technique, known as co-immunoprecipitation, was applied in **papers I and III**.

Two different IP protocols were used:

- Magnetic bead-based separation, using Dynabeads<sup>®</sup> Protein G (Novex<sup>®</sup>, Life technologies) cross-linked to FLAG M2 monoclonal antibody (Sigma-Aldrich) or Dynabeads<sup>®</sup> M-270 Epoxy (Invitrogen<sup>™</sup>, Life Technologies) cross-linked to rabbit anti-Btnl1 polyclonal antibody or pre-immune serum (Moravian-Biotechnology). Cell lysates from FLAG-tagged-Btnl-pMX-IRES transduced MODE-K cells or from isolated murine small intestinal epithelial cells, were incubated with the coupled beads. Bound material was collected on a magnet and eluted.

- Protein G PLUS-Agarose (Santa Cruz Biotechnology). Cell lysates from HA-tagged-Btnl-pMX-IRES transduced MODE-K cells were incubated with anti-HA polyclonal antibody (Sigma-Aldrich). Thereafter, the immune complex was captured on a support to which the complex was immobilized (Protein G PLUS-Agarose). Finally, the immunoprecipitates were eluted from the support.

Immunoprecipitated samples were analyzed by western blotting or mass spectrometry.

### 3.12 Mass Spectrometry

Mass spectrometry (MS) is an invaluable technique in proteomics that measures the mass-to-charge ratio of ions to identify molecules in complex mixtures. In **paper I**, mass spectrometry was used for complex detection in lysates of freshly isolated small intestinal epithelial cells. Cell lysates were subjected to IP using anti-Btnl1 polyclonal antibody or pre-immune serum (Moravian-Biotechnology), run on SDS-PAGE gel, and Coomassie-stained with Imperial™ Protein Stain (Thermo Scientific) for band excision and mass spectrometry analysis.

The proteins were in-gel digested with trypsin (Promega), and the eluted peptides were analyzed by nanoflow liquid chromatography tandem mass spectrometry (nLC-MS/MS) using an Easy-nLC™ 1000 system (Thermo Scientific) coupled to a Q-Exactive™ mass spectrometer (Thermo Scientific) through a nanoelectrospray ion source. Data were analyzed against the *Mus Musculus* NCBI database (29-May-2015) using the Mascot protein identification program (Matrix Science), which identifies proteins from peptide sequence databases.

### 3.13 Quantitative real-time PCR

Quantitative polymerase chain reaction (qPCR) allows the quantitation of genes in biological samples. In combination with reverse-transcription PCR, which performs complementary DNA (cDNA) synthesis from RNA, qPCR can be used to quantitate changes in gene expression. In **papers II-IV**, qPCR was used to measure gene expression of human and murine *BTN* and *BTNL*, and human *IL-6* genes. qPCR uses fluorescent reporter molecules to monitor the amplification of products during each cycle of the PCR reaction. In these studies, GoTaq® qPCR Master Mix (Promega) containing the double-stranded DNA-intercalating dye agent BRYT Green® was used.

Before qPCR analysis, RNA extraction from the tissues of interest (murine intestinal tissue in **papers II-IV**, and colon biopsies from patients in **paper IV**), and cDNA preparation were performed. Human and murine tissues were lysed and homogenized (Tissuelyser II, Qiagen), and total RNA was isolated using RNeasy® mini kit (Qiagen), including DNase I digestion. RNA concentration and purity was determined using the spectrophotometer NanoDrop ND-1000. The Omniscript® Reverse Transcriptase kit (Qiagen) and the SuperScript™ III Reverse Transcriptase kit (Invitrogen™, Life



Technologies) were used for cDNA synthesis for human and murine samples, respectively.

Quantitative PCR was performed using GoTaq® qPCR Master Mix according to manufacturer's instructions (Promega) on a LightCycler480 thermal cycler (Roche). Each qPCR analysis was run in duplicate. The sequences of the PCR primers (Eurofins MWG Operon and Applied Biosystems) used in **papers II-IV** are listed in **Table 1**. Gene expression was assessed with the  $2^{-\Delta Ct}$  method using human *HPRT1* or murine  $\beta$ -*actin* as housekeeping genes.

**Table 1.** Primer sequences used for qPCR.

Gene	Primer sequence	
	Forward	Reverse
<b>Human</b>		
<i>HPRT1</i>	Primers were purchased from Applied Biosystems (Hs99999909_m1)	
<i>BTN1A1</i>	5'-ggatggaagctacgaagaagc-3'	5'-tgcatactgatgtgagggtca-3'
<i>BTN2A1</i>	5'-aggagaccagatttcgtttcct-3'	5'-agggcagcagctgattccat-3'
<i>BTN2A2</i>	5'-gaagcagctcctacgatga-3'	5'-tggccttgatttcaatgag-3'
<i>BTN3A1</i>	5'-tcagaggggaatgctaagagg-3'	5'-caagtatggtgaccgaagaaga-3'
<i>BTN3A2</i>	5'-ctccaatgggaataccaagg-3'	5'-gggaacttgccatttctatca-3'
<i>BTN3A3</i>	5'-actcaagtggaggaaaatccagt-3'	5'-tggcagatcccgcggctct-3'
<i>BTNL2</i>	5'-agaaggggtcggctcatcag-3'	5'-gctgtatatcttctcccactctgac-3'
<i>BTNL3</i>	5'-tcagtttctacgagctgggtgc-3'	5'-ccaagcctggacaaaact-3'
<i>BTNL8</i>	5'-gctctcatgctcagtttggtt-3'	5'-gtctggcccaaacacctg-3'
<i>BTNL9</i>	5'-tcttgtcttctcatgcacct-3'	5'-gcctagcaccttgacctctg-3'
<i>IL6</i>	Primers were purchased from Applied Biosystems (Hs00985639_m1)	
<b>Murine</b>		
$\beta$ - <i>actin</i>	5'-cttcttgcagctcctcgtt-3'	5'-aggagtccttctgacctatgc-3'
<i>Btn1a1</i>	5'-tactggccttaggatttccacc-3'	5'-gacgtgaatctccaatcgaact-3'
<i>Btn2a2</i>	5'-tggagacgaaccttcatatg-3'	5'-cacatggacggcagcacaatc-3'
<i>Btnl1</i>	5'-tgaccaggagaatcgaagg-3'	5'-caccgagcaggaccaatagt-3'
<i>Btnl2</i>	5'-ttacaatgccagaacttcg-3'	5'-ttccatctctgtccctccac-3'
<i>Btnl4</i>	5'-cattctctcagagaccacacta-3'	5'-gagaggcctgaggaagaa-3'
<i>Btnl6</i>	5'-atccttggagatccacagtga-3'	5'-gggagagaccttgggaaga-3'
<i>Btnl9</i>	5'-ccccttagagggagggtga-3'	5'-aatactgagaatctgccatctgtc-3'

### 3.14 Statistical analysis

Two statistical methods, parametric and non-parametric, were applied in data analysis. Parametric tests assume a normal distribution of the data, whereas non-parametric tests rely on no assumptions of the data's distribution.

In **papers I-III**, parametric statistics were used. The unpaired two-tailed t-test was used for comparison between two independent groups, while One-Way ANOVA followed by Holm-Sidak's multiple comparisons test was applied to evaluate differences between three or more groups. Correlation between parameters was determined using Pearson correlation test.

In **paper IV**, non-parametric statistics were applied. The unpaired two-tailed Mann-Whitney test was used for comparison between two independent groups, while Kruskal-Wallis test followed by Dunn's multiple comparisons test was applied to evaluate differences between three groups. Statistical significance between two paired groups was determined by Wilcoxon matched-pairs signed-ranks test. Correlation between parameters was determined using Spearman correlation test.

Differences were considered statistically significant when  $P < 0.05$  (\* $P \leq 0.05$ , \*\* $P \leq 0.01$ , \*\*\* $P \leq 0.001$ , and \*\*\*\* $P \leq 0.0001$ ). All data were generated using GraphPad Prism version 6.04.

## 4. RESULTS AND DISCUSSION

For many years, body surface epithelia was viewed to primarily contribute to host protection through its physicochemical barrier functions, however, there is emerging evidence that epithelial cells are able to stimulate IELs and hence, to regulate immune responses. This notwithstanding, few molecules used by epithelial cells to instruct immune cells in the intestine have been identified. Defining the interactions involved in the epithelial cell – IEL cross-talk is therefore crucial, not only to improve our understanding of the biology of T cells that reside in intestinal mucosa, but also to give new insights into the immune activation and perhaps more importantly, into immune dysregulation in infectious-, inflammatory- and carcinogenic stress in the gut.

The text below summarizes the findings of the four papers included in this thesis. The results from **Papers I-III**, which focus on the study of the murine, intestine localized Btl family members, will first be described. This will be followed by discussion of data in **Paper IV** that presents a comprehensive expression analysis of human and murine *BTN* and *BTNL* genes in colonic inflammation and cancer.

Bas et al. previously reported that the expression of *Btl1*, *-4* and *-6* transcripts is largely restricted to small intestinal epithelial cells, and that Btl1 protein, detected on the surface of iECs and located in direct juxtaposition with IELs, is implicated in the regulation of activated intestinal IELs by suppressing local pro-inflammatory signals [151]. Therefore, in **papers I-III**, we focused on the characterization of Btl4 and Btl6 as possible novel epithelial immune regulators.

### 4.1. Btl protein expression and the proteins' biological forms (Papers I and III)

To study the expression of Btl4 and Btl6 proteins, we generated rabbit polyclonal anti-Btl4 and anti-Btl6 antibodies. Despite several attempts to generate antibodies recognizing the native form of the Btl4 and Btl6 proteins, the developed anti-sera only recognized the proteins in their reduced form and thus, could not be used for *in situ* studies. To overcome this obstacle, we turned to molecular biology and generated tools that allowed us to study proteins' expression and function *in vitro*. Thus, we constructed Btl1, *-4* and *-6* cDNAs that included a FLAG or HA epitope C

terminal to the putative signal cleavage site, and that were cloned into bicistronic pMX-IRES-GFP expression vectors. Murine small intestinal epithelial MODE-K cells, which do not ordinarily express Btl proteins, were then transfected with these constructs.

Using the generated antibodies in western blotting under reducing conditions, we demonstrated that Btl6 protein is exclusively expressed in the intestine, and that its expression in the small intestine is confined to iECs. We further demonstrated that also Btl4 protein is expressed in epithelial cells in the small intestine. These data are consistent with the previously published mRNA data by Bas et al. [151].

Moreover, the anti-Btl4 antibody detected two bands in lysates from primary small intestinal epithelial cells and from Btl4 transfected MODE-K cells. Size-reduction of the bands upon N-glycosidase F treatment of Btl4 transfected MODE-K cell lysates indicated the existence of two glycosylated forms of the Btl4 protein. Protein glycosylation has been reported to be involved in biological recognition, where their structure diversity provides signals for protein targeting and cell - cell interactions [223]. Intriguingly, binding of human BTN2A1 to DC-SIGN, which modulates immature monocyte-derived dendritic cells, was revealed to be dependent on tumor-specific glycosylation of the BTN2A1 protein [152]. Thus, distinct glycosylation of the Btl4 protein may lead to different protein's interactions and hence, to different outcomes depending of local conditions such as intestinal homeostasis or stress.

Whereas Btl4, like Btl1, is readily expressed on the surface of small intestinal epithelial MODE-K cells, we showed that cell surface expression of Btl6 is specifically dependent on the presence of Btl1. While determining if this Btl1-dependent expression of Btl6 was mediated by Btl1-Btl6 interaction and using immunoprecipitation techniques, we identified a previously unknown Btl1-Btl6 complex displayed on the cell surface of small intestinal MODE-K cells. Mass spectrometry of anti-Btl1 immunoprecipitated lysates from primary small intestinal epithelial cells revealed a non-reduced Btl1 homodimer complex of ~130 kDa, and a high molecular mass Btl1-Btl6 heteromeric complex and thus, identified the presence of Btl1-Btl6 protein complex formation *in vivo*. We additionally demonstrated that Btl4 can exist both as a homomer and as a Btl1-Btl4 heteromeric structure on the surface of small intestinal MODE-K cells. The observed Btl1-Btl4 and Btl1-Btl6 heteromerizations may explain the inability of the generated antibodies, in particular the anti-Btl6 antibody, to

recognize the native form of the proteins, most likely due to epitope masking after complex formation.

Altogether, our data demonstrate the presence of multiple Btl forms comprising various combinations of the iEC-specific Btl proteins, which may result in different or even divergent functions of the Btl proteins determined by their composition. However, the high homology between Btl4 and Btl6 (88% amino acid identity in the ectodomain [126]) and their capacity to form heteromeric complexes with Btl1, may also imply redundant functions of the Btl molecules in the intestinal epithelium.

## **4.2. Btl expression in the absence of gut microbiota and in the ontogeny (Papers II and III)**

During early neonatal life, namely at birth and at weaning, important changes occur in the gut. The infant's immature intestinal immune system develops as it comes into contact with microbial and dietary antigens. Thus, both microbial colonization and diet have a decisive role in the complete development of the mucosal immune system [224].

To assess the impact of the gut microbiota on Btl protein expression, we examined the presence of Btl1 and Btl6 proteins in germ-free mice. We found that the expression of Btl1 and Btl6 proteins in the neonate gut is not dependent of microbial colonization, as Btl1 and Btl6 proteins are present in germ-free mice at comparable levels to those detected in conventional mice.

Furthermore, to gain insight into how the weaning event regulates the expression of Btl proteins, we investigated the presence of Btl1, Btl4 and Btl6 proteins in the small intestine of newborn, 1-4 week-old and compared the expression to adult mice. We found that the expression of Btl1, -4 and -6 proteins is delayed during ontogeny and appears in the small intestinal epithelium of 2-3 week-old pre-weaning pups. This delay was not reflected at the RNA level, where the *Btl* expression is already detected in the newborn small intestine, suggesting post-transcriptional regulation during mouse intestinal maturation. Although the appearance of Btl proteins occurs before weaning, where pups are mainly fed with milk, we cannot determine whether an increased exposure to pelleted food and thus, to dietary antigens, is involved in the expression of Btl proteins, or if the expression is regulated by an unknown developmental factor.

### 4.3. Immunological role of Btl proteins (Papers I and II)

The primarily restricted expression of Btl proteins in gut epithelium and the reported suppression of co-stimulation-induced IEL activation by Btl1 [151], suggest that other iEC-specific Btl molecules may have similar capacity to effect IEL - epithelial cell communication.

To further study immunomodulatory roles of the Btl molecules on IEL response, we performed *in vitro* T cell proliferation assays, exploiting a culture system that overcomes the rapid apoptosis of IELs *ex vivo* [225, 226] and that permits IELs to be rested and then re-activated when stimulated via the TCR [151, 222]. *Ex vivo* IELs, which lack or have low levels of CD25 [16], or splenocytes were co-cultured with Btl1-, Btl1-Btl6- or pMX- (empty vector) transfected small intestinal epithelial MODE-K cells. The reliability of the co-culture system was verified by confirming previously reported suppressive effect of Btl1-Fc on CD3-activated peripheral T cells [208]. Thus, we proved that under anti-CD3 and anti-CD28 stimulation, splenocyte proliferation is reduced in the presence of both Btl1 and Btl1-Btl6 complex.

In contrast, we found no significant reduction or increase of IEL proliferation by either Btl1 or Btl1-Btl6 complex in the presence of anti-CD3 stimulation. Instead, we demonstrated the capacity of Btl1 and Btl1-Btl6 complex to induce IEL proliferation in the absence of exogenous activation. This ability is dependent of the presence of IL-2 or IL-15, as no proliferation was detected in the absence of these cytokines, and is specific for IELs, as no proliferation was observed in unstimulated splenocytes. Although the Btl1-Btl6 complex is not critical for promoting IEL proliferation, we revealed that the Btl1-Btl6 complex specifically enhances the expansion of IELs bearing the V $\gamma$ 7V $\delta$ 4 receptor. Altogether, our data imply the contribution of the epithelium-specific Btl proteins to the upkeep of the intestinal IEL pool. Proliferation of intestinal IELs *in situ* in the absence of activation had been demonstrated by previous studies [227, 228], however, the mechanisms behind the homeostatic expansion of IELs has to our knowledge not been fully defined.

In addition, we found that Btl- transfected MODE-K cells up-regulate CD25 expression on both TCR $\alpha\beta$ <sup>+</sup> IELs and TCR $\gamma\delta$ <sup>+</sup> IELs in the absence of TCR stimulation, and that the observed proliferation is restricted to IELs up-regulating CD25. Although CD25 expression was significantly up-

regulated on IELs in the presence of Btl proteins and exogenous IL-2, CD25 induction could additionally be observed in conditions with IL-2 and MODE-K cells transfected with pMX. In contrast, in conditions with exogenous IL-15, CD25 expression was only up-regulated on IELs in the presence of Btl proteins, and was not observed when IELs were co-cultured with pMX- transfected MODE-K cells. In view of the fact that co-cultures with exogenous IL-15, which is constitutively expressed by iECs [229-231], will better reproduce homeostatic conditions in the small intestine than IL-2, which is only available at low levels in the gut under steady state-conditions [232], our data suggest that the IEL proliferation is dependent on the synergy between IL-15 and Btl proteins. Additionally, we demonstrated that this effect is reliant on direct iEC - IEL contact, as no CD25 expression was found in co-cultures where MODE-K cells and IELs were separated by transwells.

Furthermore, we reported that Btl proteins can also induce IFN- $\gamma$  secretion by IELs in the absence of anti-CD3 activation and in the presence of exogenous IL-15. Taking into account that some studies have shown a protective role of IFN- $\gamma$  in the removal of transformed epithelial cells under steady-state conditions [74], this IFN- $\gamma$  secretion by IELs in the absence of TCR stimulation may contribute to the maintenance of the homeostasis in the intestinal epithelium. As the IFN- $\gamma$  production by IELs was significantly higher in the presence of Btl1 compared to Btl1-Btl6 complex, this may reflect different efficiency in regulating IEL function, or even indicate that Btl6 counter-act the effect of Btl1.

The identified iEC-expressed Btl1-Btl6 heteromeric complex has, as discussed above, a specific biological role particularly elevating the proliferation of intestinal intraepithelial V $\gamma$ 7V $\delta$ 4 T cells under “steady-state” conditions *in vitro*. To assess the association between the Btl proteins and the IEL repertoire in the small intestine *in vivo*, we examined the  $\gamma\delta$  expressing IEL repertoire during the first weeks of neonatal development in the murine small intestine, and found that the expansion of V $\gamma$ 7V $\delta$ 4 IELs in the neonate gut correlates with the appearance of the Btl1 and Btl6 proteins at 3 weeks of age. Our data are consistent with studies demonstrating an increase in the percentage of  $\gamma\delta$  IELs detected at 2-3 weeks of age in the small intestine of neonatal mice [26-28]. Moreover, observations reporting extra-thymic origin of  $\gamma\delta$  IELs [17, 20, 22], and the reported linkage between the intestinal  $\gamma\delta$  TCR repertoire and the MHC class II locus [56, 233], which intriguingly contains the *Btl1* and *Btl6* genes, imply that the gut population of IELs may be governed by gut micro-

environmental factors rather than by immigration of thymus-derived T cells and thus, support our data.

Furthermore, our results showing comparable levels of Btl1 and Btl6 proteins in GF and CV mice are supported by earlier publications demonstrating a significant difference in the number of  $\alpha\beta$  IELs, but no differences in the frequency of  $\gamma\delta$  IELs between GF and CV mice [29, 30].

Taken together, and in accordance with the suggestion that the IEL colonization process may be regulated by gut micro-environmental factors, our data suggest that the homeostatic expansion of IELs in the gut is driven by iEC-specific Btl proteins. Curiously, our finding describing that Btl1-Btl6 complex enhances the expansion of V $\gamma$ 7V $\delta$ 4 IELs is similar to the one observed for the skin epithelium resident Skint-1, a close relative to Btl1 and Btl6 that regulates epidermal V $\gamma$ 5V $\delta$ 1 IEL development [122-124].

#### 4.4. Human and murine *BTN* and *BTNL* gene expression in normal colon (Paper IV)

Although significant progress has been made in understanding the role of Btl and Btl molecules in modulation of T cell mediated immune responses, little is still known about the molecules' implication in inflammatory and proliferative disorders. Hence, in **paper IV**, we investigated how the *BTN* and *BTNL* genes are regulated in intestinal inflammation and cancer.

We first assessed the expression of *BTN* and *BTNL* genes in normal colon from human and mouse by quantitative real-time PCR. Variable *BTN* and *BTNL* mRNA expression levels were identified. In human colon, *BTN2A1*, *BTN2A2*, *BTN3A1*, *BTN3A2*, *BTN3A3*, *BTNL3* and *BTNL8* genes showed relatively high expression levels, whereas *BTN1A1*, *BTNL2* and *BTNL9* genes were present at low levels. In murine colon, *Btl1* and *Btl4* genes were expressed at relatively high levels, *Btl1a1*, *Btl2* and *Btl6* genes were found at intermediate levels, and *Btl2a2* and *Btl9* transcripts were on the limit of detection.

*Btl9* mRNA expression pattern had not been characterized before and thus, we examined its expression in a panel of mouse tissues. We found that liver and mesenteric lymph nodes had the highest expression of *Btl9* compared to thymus and spleen, and that *Btl9* was not expressed in small intestine.



## 4.5. Human *BTN* and *BTNL* gene expression in intestinal inflammation and cancer (Paper IV)

Over the recent years, *BTN* and *BTNL* molecules have been genetically linked to various immunological diseases. Polymorphisms in the human *BTNL2* gene have been associated with inflammatory disorders such as sarcoidosis [154-163], ulcerative colitis [164-166], rheumatoid arthritis [167, 168] and myositis [169]; and to prostate cancer [173]. Furthermore, a few studies have identified an association between human *BTN3* and ovarian cancer [174-176].

As several human *BTN* and *BTNL* genes are expressed in the intestine, they may be involved in gastrointestinal disorders. We used qPCR to map their expression in colon samples from patients with ulcerative colitis, irritable bowel syndrome and colon tumors. Expression in UC and IBS patients was compared to the expression in healthy subjects with no prior history of gastrointestinal diseases, while expression in the tumor of colon cancer patients was compared to adjacent unaffected mucosa from the same individuals.

Our analysis revealed a significant up-regulation of *BTN1A1*, *BTN2A2*, *BTN3A2* and *BTN3A3* genes in UC patients compared to healthy subjects. By contrast, the expression of most of the *BTNL* genes was unchanged, with the exception of *BTNL8* that was significantly down-regulated (**Table 2**). Our data showing unchanged levels of *BTNL2* in UC patients suggest that the reported *BTNL2* SNPs associated with susceptibility to UC [164-166] affects the encoded *BTNL2* protein instead of the *BTNL2* gene expression, as in the case of sarcoidosis, where the resulting protein lacks the C-terminal IgC domain and the transmembrane helix, thereby disrupting the membrane localization of the protein [154]. Moreover, our data presenting an opposite expression pattern of *BTN3* genes and *BTNL8* gene in UC patients correlate with the divergent ability of these molecules to modulate peripheral T cell activation. If *BTN3*, reported to inhibit T cell proliferation and cytokine secretion [174, 186], and *BTNL8*, described to trigger T cell activation [194], exhibit analogous functions in the intestine, the outcome of an up-regulation of *BTN3* and a down-regulation of *BTNL8* in an inflamed scenario, would be to attenuate the T cell mediated immune response and thus, to limit progression to chronic inflammation. In addition, we demonstrated an inverse correlation between *BTN3A3* and *IFN $\gamma$* , where increased expression of *BTN3A3* associates with decreased expression of *IFN $\gamma$* . *IFN $\gamma$*  has

## Results and Discussion

previously been reported to be increased in UC patients [234], thus, our results further suggest a feedback mechanism to limit the effect of inflammation in the colon of UC patients.

Whereas inflammatory bowel diseases, namely Crohn's disease and UC, are characterized by macroscopic signs of inflammation or ulceration in the small and large intestine, such changes are not present in irritable bowel syndrome [235]. Our data showed normal *BTN* and *BTNL* gene expression in IBS patients compared to healthy individuals, implying that the altered expression of *BTN* and *BTNL* genes in UC patients is driven by inflammation.

Furthermore, our analysis indicated unchanged expression levels of *BTN* genes in tumor tissue of colon cancer patients compared to adjacent unaffected tissue from the same subjects. By contrast, *BTNL2*, *BTNL3*, *BTNL8* and *BTNL9* genes were significantly down-regulated (**Table 2**). In view of recent studies demonstrating the ability of BTNL molecules to regulate T cell mediated immune responses, where BTNL8 was reported to enhance T cell activation [194], it is logical to speculate that a down-regulation of *BTNL* genes in the tumor may have implications in immune surveillance and tumor promotion.

**Table 2.** Human *BTN* and *BTNL* gene expression data.

	UC patients	Colon cancer patients
<i>BTN1A1</i>	↑↑↑	↔
<i>BTN2A1</i>	↔	↔
<i>BTN2A2</i>	↑↑↑	↔
<i>BTN3A1</i>	↔	↔
<i>BTN3A2</i>	↑	↔
<i>BTN3A3</i>	↑↑↑↑	↔
<i>BTNL2</i>	↔	↓↓
<i>BTNL3</i>	↔	↓↓
<i>BTNL8</i>	↓↓↓	↓↓↓
<i>BTNL9</i>	↔	↓

↑ indicates significant up-regulation (↑  $P \leq 0.05$ , ↑↑  $P \leq 0.01$ , ↑↑↑  $P \leq 0.001$ , and ↑↑↑↑  $P \leq 0.0001$ ).

↓ indicates significant down-regulation (↓  $P \leq 0.05$ , ↓↓  $P \leq 0.01$ , ↓↓↓  $P \leq 0.001$ , and ↓↓↓↓  $P \leq 0.0001$ ).

↔ indicates no significant up- or down-regulation.

## 4.6. Murine *Btn* and *Btnl* gene expression in intestinal inflammation and cancer (Paper IV)

Humans and mice are surprisingly similar, sharing between 95-98% of our genomes and getting most of the same diseases. The ease with which the murine genome can be manipulated has provided a powerful tool to create useful mouse models of IBD and intestinal cancer.

To better understand the role of *Btn* and *Btnl* molecules in inflammatory and proliferative disorders, we examined the expression of murine *Btn* and *Btnl* genes in intestinal samples from mouse models of spontaneous colitis (*Muc2*<sup>-/-</sup>) and intestinal tumorigenesis (*Apc*<sup>Min/+</sup>). Expression in distal, middle and proximal large intestine of *Muc2*<sup>-/-</sup> mice was compared to the expression in *Muc2*<sup>+/-</sup> mice, which served as controls. Expression in the small intestinal polyps derived from *Apc*<sup>Min/+</sup> mice was compared to adjacent unaffected tissue from the same mice.

Our analysis revealed a significant down-regulation of *Btn1a1*, *Btnl1*, *Btnl4*, *Btnl6* and *Btnl9* genes in the distal part of the colon of *Muc2*<sup>-/-</sup> mice compared to control mice. By contrast, no differences were found in the expression levels in the proximal part (**Table 3**). In both UC patients and *Muc2*<sup>-/-</sup> mice, signs of inflammation and destruction of colon architecture increase proximally from the distal part, where the inflammation is most pronounced [212, 213, 236, 237]. Thus, our data suggest that the altered expression of *Btn* and *Btnl* genes is related to inflammation. The down-regulation of *Btnl1*, *Btnl4* and *Btnl6* genes was particularly intriguing since these genes are essentially restricted to intestinal epithelia. *Btnl1* has been reported to attenuate the epithelial response to activated IELs, resulting in reduced production of pro-inflammatory mediators such as IL-6 and CXCL1, which are involved in promoting influx of monocytes and neutrophils [151, 238, 239], and our data have demonstrated the ability of *Btnl1* and *Btnl6* to promote IEL proliferation. Hence, as intestinal  $\gamma\delta$  IELs contribute to preservation and restoration of the gut integrity in colitis [33, 41, 86, 93, 95], a down-regulation of the intestine-specific *Btnl1* and *Btnl6* genes may contribute to progression of the ongoing inflammation and to impair tissue integrity's repair.

The analysis of *Btn* and *Btnl* genes in *Apc*<sup>Min/+</sup> mice revealed significantly increased expression levels of *Btn1a1* and *Btn2a2* genes in isolated small intestinal polyps compared to adjacent unaffected tissue from the same mice. In contrast, levels of *Btnl1* transcripts were significantly decreased (**Table 3**).

The consequence of an up-regulation of *Btn1a1* and *Btn2a2*, reported to inhibit T cell activation [153] and to induce Treg development [203], may be to contribute to immune evasion and tumor promotion. This is consistent with a study revealing potentiated anti-tumor responses in *Btn2a2*<sup>-/-</sup> mice [204]. In addition, a down-regulation of *Btnl1*, described to suppress epithelial cell production of pro-inflammatory IL-6 and CXCL1 in response to activated intestinal IELs [151], may further contribute to tumor progression as enhanced levels of both IL-6 and CXCL1 have been reported to participate in development of intestinal cancer [240-242]. Attenuated levels of *Btnl1*, which promotes IEL proliferation, may result in a reduced number of IELs and consequently in reduced IEL-cytotoxic activity to kill transformed epithelial cells [87-89], farther promoting tumor development.

**Table 3.** Murine *Btn* and *Btnl* gene expression data.

	<i>Muc2</i> <sup>-/-</sup> mice			<i>Apc</i> <sup>Min/+</sup> mice TUM
	Proximal	Middle	Distal	
<i>Btn1a1</i>	↔	↔	↓	↑
<i>Btn2a2</i>	↔	↔	↔	↑↑
<i>Btnl1</i>	↔	↓↓↓	↓↓↓↓	↓
<i>Btnl2</i>	↔	↔	↔	↔
<i>Btnl4</i>	↔	↓	↓↓	↔
<i>Btnl6</i>	↔	↓	↓↓	↔
<i>Btnl9</i>	↔	↔	↓	ND

↑ indicates significant up-regulation (↑ P≤0.05, ↑↑ P≤0.01, ↑↑↑ P≤0.001, and ↑↑↑↑ P≤0.0001).

↓ indicates significant up-regulation (↓ P≤0.05, ↓↓ P≤0.01, ↓↓↓ P≤0.001, and ↓↓↓↓ P≤0.0001).

↔ indicates no significant up- or down-regulation.

In conclusion, our results showing an altered expression of the *BTN* and *BTNL* genes in colonic inflammation and intestinal tumors, further attest these genes as active players in the orchestration of immune responses and thus, affirm the importance of these genes in the immune system both in health and in disease.

## 5. CONCLUDING REMARKS

Btn and Btnl proteins have over the past decade emerged as essential regulators of T cell functions in mice and humans. Heretofore, much of attention has been focused on assessing the proteins' biological effects on systemic T cells, and only few studies have attempted to understand their capacity to regulate the activity of local intraepithelial T cells. Their elucidation is an important step in understanding tissue-specific inflammatory diseases and associated carcinoma, as well as host defense.

Bas et al. previously showed that the expression of *Btnl1*, *Btnl4* and *Btnl6* genes is largely restricted to epithelial cells in the gut, and that Btnl1 is a novel tissue-specific regulator of intestinal epithelial cell - intraepithelial T cell cross-talk, being able to attenuate the epithelial response to activated TCR $\alpha\beta$ <sup>+</sup> and TCR $\gamma\delta$ <sup>+</sup> IELs. This observation, together with our data demonstrating an up-regulation of IEL activation and proliferation dependent of Btnl proteins in conditions without exogenous activation, suggest that the interaction between IELs and Btnl proteins may lead to different outcomes depending on local conditions, e.g., intestinal homeostasis or inflammatory stress. While attenuation of epithelial response to activated IELs may be important in controlling an inflammatory response and progression to chronic inflammation, induction of TCR $\alpha\beta$ <sup>+</sup> and TCR $\gamma\delta$ <sup>+</sup> IEL activation and proliferation in the absence of exogenous stimulation may contribute to the maintenance of the intestinal IEL pool. Moreover, we have identified the existence of previously unknown multimeric complexes comprising various combinations of the iEC-specific Btnl proteins, which may have different functions determined by their form, and demonstrated that the Btnl1-Btnl6 heteromeric complex, expressed in primary small intestinal epithelial cells, has a specific biological role particularly enhancing the expansion of IELs bearing the V $\gamma$ 7V $\delta$ 4 receptor in *in vitro* studies. In addition, we examined the  $\gamma\delta$  expressing IEL repertoire during the first weeks of neonatal development in the murine small intestine, and found that the expansion of V $\gamma$ 7V $\delta$ 4 IELs in the neonate gut correlates with the appearance of the Btnl1 and Btnl6 proteins at 3 weeks of age. Although further experiments, for example using Btnl<sup>-/-</sup> approaches, will be necessary to confirm the association between the Btnl1-Btnl6 complex and the *in vivo* proliferation of V $\gamma$ 7V $\delta$ 4 IELs, these *in situ* data further add strength to our *in vitro* results.

## Concluding Remarks

---

Although T cell regulation by Btn and Btnl molecules is now unfolding, the molecules' implication in inflammatory and proliferative disorders is poorly defined. Therefore, we present a comprehensive expression analysis of human and murine *BTN* and *BTNL* genes in colonic inflammation and intestinal tumor. We demonstrated a substantial and significant modulation of several of the genes in ulcerative colitis and colon cancer and hence, our data suggest an inflammation driven- regulation of *BTN* and *BTNL* genes. Altogether, these data represent a valuable resource proposing several Btn and Btnl candidates to further investigate UC and colon cancer susceptibility.

In conclusion, this thesis work has demonstrated that iEC-specific Btnl proteins are involved in the regulation of IEL activity in the gut, and that Btn and Btnl genes are associated with bowel pathology. These findings shed new light on the elucidation of local immune regulation in the gut and the contribution of the Btn and Btnl molecules to pathophysiology. Nonetheless, further studies are necessary to identify the family's full immunomodulatory capacity, e.g. by identifying their binding partners, to, in the future, be able to use them as clinical targets.

# ACKNOWLEDGEMENTS

More than five years since I came to Gothenburg as an Erasmus student, and now I am here about to finish my PhD studies. I would never have thought to stay in Gothenburg so long and to have this incredible life experience. Sweden has become my second home and I could not imagine a better country, other than Spain, to live in. There are a number of people who have journeyed with me during my PhD period and to whom I am greatly grateful.

First of all, I would like to thank everyone in the **Department of Microbiology and Immunology**. It has been a pleasure working with all of you in such a nice and friendly environment.

**Anna Bas-Forsberg**, my supervisor. I heartfelt thank you for giving me the opportunity to work with you and for always believing in me. I am so grateful for your scientific guidance throughout this thesis work, and for all your support and encouragement. The path towards this dissertation has been circuitous, but we did it!

**Gunnar Hansson**, my co-supervisor. Thank you for sharing your knowledge with me in fruitful scientific discussions.

To all **my collaborators**, thank you for productive team-work. A special mention to: **Thaher Pelaseyed** and **Joakim Bergström**, thanks for your work with immunoprecipitation and mass spectrometry techniques, and for your advice in proteomics; **Alex Wenzel**, thanks for your help running a thousand of qPCR plates, and for your assistance with the flow cytometer and the sorter; **Lena Öhman**, **Marianne Quiding-Järbrink** and **Susanna Cardell**, thank you for providing me with human and murine samples of biological material, as well as for nice scientific discussions.

**María Fernández** and **Enrique Joffré**, my Swedish siblings. Nothing would have been the same without you, both in the lab and outside: memorable trips, parties and dinners. **María**, thanks for always being there, not only in the best moments but also in the difficult ones. **Quique**, thanks for your

## Acknowledgements

---

happiness, your crazy stories and for being my companion during late nights at the lab. My changos, I miss you so much!

To all former and present **PhD students**, especially to my roommates, thanks for creating a joyful and international working atmosphere. A big thank you to **Paulina Akeus** and **Stefan Karlsson**, for your kindness and for nice “fikas”, dinners and other great moments.

To the sixth floor, in particular to **Karin Schön**, **Lena Ekman** and **Anneli Stensson**, thank you for your generous technical support and for always being helpful, no matter what I ask for; and to **Zou Xiang** and **Yu Fang**, many thanks for your amiability, nice chatting and lovely gifts from China.

To the department of Medical Biochemistry and Cell Biology, especially to **Ana Rodríguez**, thanks for charming conversations and for sharing your expertise not only in the lab, but also in the everyday life.

To the core facility Mammalian Protein Expression, in particular to **Malin Bäckström**, thank you for teaching me the western blot technique; to the Centre for Cellular Imaging, especially to **Julia Fernández-Rodríguez**, thank you for good advice and assistance in confocal microscopy; and to **Linda Bergqvist**, thank you for your help with cell sorting.

**Pia Axelsson**, from EBM. Thank you for taking good care of all my mice and helping me whenever I have needed you.

To **Susanne Uhlan** and the **administrative staff** at the department, thank you for being so helpful with technical and administrative support.

My friends in Gothenburg, especially **Jairo**, **Pamela**, **Elisa** and **Elena**. Thanks for truckloads of great times, everyday lunches and unforgettable parties and trips. I am so happy to have shared these years with you! A huge thank you also to **Paloma**, **Ana** and **Leyla**, for your friendship and care during the first months of my PhD studies.

The **Morate's family**: **Álex**, **Carol** and your lovely daughters **Lyra** and **Norah**. Many thanks for your hospitality, help and support during these years, and for all good moments we have spent together.



Mi familia, **mis padres y hermanas Raquel y Patri**. Gracias por vuestro amor y apoyo incondicional, y por siempre estar ahí, a pesar de la distancia. Porque todo lo que soy es gracias a vosotros. ¡Os echo mucho de menos y os quiero!

**Nacho**, mi “amore”. You are, without doubt, the best thing that has happened to me during this period. Thanks for your invaluable love, patience, comprehension and support during these years, and for being part of my life. Together we will always succeed. ¡Te quiero!

This thesis work was supported by grants from the Swedish Research Council (grant no. 621-2011-4917), Åke Wibergs Foundation (grant no. 924562501), Magnus Bergvalls Foundation, and Ollie and Elof Ericssons Foundation.



# REFERENCES

1. Borghesi L, Milcarek C: Innate versus adaptive immunity: a paradigm past its prime? *Cancer research* 2007, 67(9):3989-3993.
2. Lanier LL: Shades of grey - the blurring view of innate and adaptive immunity. *Nature reviews Immunology* 2013, 13(2):73-74.
3. Ferguson A: Intraepithelial lymphocytes of the small intestine. *Gut* 1977, 18(11):921-937.
4. Jameson JM, Sharp LL, Witherden DA, Havran WL: Regulation of skin cell homeostasis by  $\gamma\delta$  T cells. *Frontiers in bioscience : a journal and virtual library* 2004, 9:2640-2651.
5. Holtmeier W, Pfander M, Hennemann A, Zollner TM, Kaufmann R, Caspary WF: The TCR- $\delta$  repertoire in normal human skin is restricted and distinct from the TCR- $\delta$  repertoire in the peripheral blood. *The Journal of investigative dermatology* 2001, 116(2):275-280.
6. Lefrancois L, Lycke N: Isolation of mouse small intestinal intraepithelial lymphocytes, Peyer's patch, and lamina propria cells. *Current protocols in immunology / edited by John E Coligan [et al]* 2001, Chapter 3:Unit 3 19.
7. Hayday A, Theodoridis E, Ramsburg E, Shires J: Intraepithelial lymphocytes: exploring the Third Way in immunology. *Nature immunology* 2001, 2(11):997-1003.
8. Cheroutre H, Lambolez F, Mucida D: The light and dark sides of intestinal intraepithelial lymphocytes. *Nature reviews Immunology* 2011, 11(7):445-456.
9. Latthe M, Terry L, MacDonald TT: High frequency of CD8 $\alpha\alpha$  homodimer-bearing T cells in human fetal intestine. *European journal of immunology* 1994, 24(7):1703-1705.
10. Abadie V, Discepolo V, Jabri B: Intraepithelial lymphocytes in celiac disease immunopathology. *Seminars in immunopathology* 2012, 34(4):551-566.
11. Steiner G, Koning F, Elbe A, Tschachler E, Yokoyama WM, Shevach EM, Stingl G, Coligan JE: Characterization of T cell receptors on resident murine dendritic epidermal T cells. *European journal of immunology* 1988, 18(9):1323-1328.
12. Lambolez F, Mayans S, Cheroutre H: Lymphocytes: Intraepithelial. In: *eLS*. John Wiley & Sons, Ltd; 2001.
13. Guy-Grand D, Rocha B, Mintz P, Malassis-Seris M, Selz F, Malissen B, Vassalli P: Different use of T cell receptor transducing modules in two populations of gut intraepithelial lymphocytes are related to distinct pathways of T cell differentiation. *The Journal of experimental medicine* 1994, 180(2):673-679.

## References

---

14. Shires J, Theodoridis E, Hayday AC: Biological insights into TCR $\gamma\delta$ + and TCR $\alpha\beta$ + intraepithelial lymphocytes provided by serial analysis of gene expression (SAGE). *Immunity* 2001, 15(3):419-434.
15. Lefrancois L: Phenotypic complexity of intraepithelial lymphocytes of the small intestine. *Journal of immunology* 1991, 147(6):1746-1751.
16. Wang HC, Zhou Q, Dragoo J, Klein JR: Most murine CD8+ intestinal intraepithelial lymphocytes are partially but not fully activated T cells. *Journal of immunology* 2002, 169(9):4717-4722.
17. Rocha B, Vassalli P, Guy-Grand D: Thymic and extrathymic origins of gut intraepithelial lymphocyte populations in mice. *The Journal of experimental medicine* 1994, 180(2):681-686.
18. Cheroutre H, Lambolez F: The thymus chapter in the life of gut-specific intraepithelial lymphocytes. *Current opinion in immunology* 2008, 20(2):185-191.
19. Klein JR: Ontogeny of the Thy-1-, Lyt-2+ murine intestinal intraepithelial lymphocyte. Characterization of a unique population of thymus-independent cytotoxic effector cells in the intestinal mucosa. *The Journal of experimental medicine* 1986, 164(1):309-314.
20. Bandeira A, Itohara S, Bonneville M, Burlen-Defranoux O, Mota-Santos T, Coutinho A, Tonegawa S: Extrathymic origin of intestinal intraepithelial lymphocytes bearing T-cell antigen receptor  $\gamma\delta$ . *Proceedings of the National Academy of Sciences of the United States of America* 1991, 88(1):43-47.
21. Poussier P, Julius M: Thymus independent T cell development and selection in the intestinal epithelium. *Annual review of immunology* 1994, 12:521-553.
22. Nonaka S, Naito T, Chen H, Yamamoto M, Moro K, Kiyono H, Hamada H, Ishikawa H: Intestinal  $\gamma\delta$  T cells develop in mice lacking thymus, all lymph nodes, Peyer's patches, and isolated lymphoid follicles. *Journal of immunology* 2005, 174(4):1906-1912.
23. Kanamori Y, Ishimaru K, Nanno M, Maki K, Ikuta K, Nariuchi H, Ishikawa H: Identification of novel lymphoid tissues in murine intestinal mucosa where clusters of c-kit+ IL-7R+ Thy1+ lympho-hemopoietic progenitors develop. *The Journal of experimental medicine* 1996, 184(4):1449-1459.
24. Allison JP, Havran WL: The immunobiology of T cells with invariant  $\gamma\delta$  antigen receptors. *Annual review of immunology* 1991, 9:679-705.
25. Staton TL, Habtezion A, Winslow MM, Sato T, Love PE, Butcher EC: CD8+ recent thymic emigrants home to and efficiently repopulate the small intestine epithelium. *Nature immunology* 2006, 7(5):482-488.
26. Helgeland L, Brandtzaeg P, Rolstad B, Vaage JT: Sequential development of intraepithelial  $\gamma\delta$  and  $\alpha\beta$  T lymphocytes expressing CD8 $\alpha\beta$  in neonatal rat intestine: requirement for the thymus. *Immunology* 1997, 92(4):447-456.

27. Steege JC, Buurman WA, Forget PP: The neonatal development of intraepithelial and lamina propria lymphocytes in the murine small intestine. *Developmental immunology* 1997, 5(2):121-128.
28. Kuo S, El Guindy A, Panwala CM, Hagan PM, Camerini V: Differential appearance of T cell subsets in the large and small intestine of neonatal mice. *Pediatric research* 2001, 49(4):543-551.
29. Umesaki Y, Setoyama H, Matsumoto S, Okada Y: Expansion of  $\alpha\beta$  T-cell receptor-bearing intestinal intraepithelial lymphocytes after microbial colonization in germ-free mice and its independence from thymus. *Immunology* 1993, 79(1):32-37.
30. Imaoka A, Matsumoto S, Setoyama H, Okada Y, Umesaki Y: Proliferative recruitment of intestinal intraepithelial lymphocytes after microbial colonization of germ-free mice. *European journal of immunology* 1996, 26(4):945-948.
31. Guy-Grand D, Malassis-Seris M, Briottet C, Vassalli P: Cytotoxic differentiation of mouse gut thymodependent and independent intraepithelial T lymphocytes is induced locally. Correlation between functional assays, presence of perforin and granzyme transcripts, and cytoplasmic granules. *The Journal of experimental medicine* 1991, 173(6):1549-1552.
32. Barrett TA, Gajewski TF, Danielpour D, Chang EB, Beagley KW, Bluestone JA: Differential function of intestinal intraepithelial lymphocyte subsets. *Journal of immunology* 1992, 149(4):1124-1130.
33. Chen Y, Chou K, Fuchs E, Havran WL, Boismenu R: Protection of the intestinal mucosa by intraepithelial  $\gamma\delta$  T cells. *Proceedings of the National Academy of Sciences of the United States of America* 2002, 99(22):14338-14343.
34. Jameson J, Havran WL: Skin  $\gamma\delta$  T-cell functions in homeostasis and wound healing. *Immunol Rev* 2007, 215:114-122.
35. Guy-Grand D, Cuenod-Jabri B, Malassis-Seris M, Selz F, Vassalli P: Complexity of the mouse gut T cell immune system: identification of two distinct natural killer T cell intraepithelial lineages. *European journal of immunology* 1996, 26(9):2248-2256.
36. Offit PA, Dudzik KI: Rotavirus-specific cytotoxic T lymphocytes appear at the intestinal mucosal surface after rotavirus infection. *Journal of virology* 1989, 63(8):3507-3512.
37. Muller S, Buhler-Jungo M, Mueller C: Intestinal intraepithelial lymphocytes exert potent protective cytotoxic activity during an acute virus infection. *Journal of immunology* 2000, 164(4):1986-1994.
38. Charde T, Buzoni-Gatel D, Lepage A, Bernard F, Bout D: *Toxoplasma gondii* oral infection induces specific cytotoxic CD8 $\alpha\beta$ + Thy-1+ gut intraepithelial

## References

---

- lymphocytes, lytic for parasite-infected enterocytes. *Journal of immunology* 1994, 153(10):4596-4603.
39. Lepage AC, Buzoni-Gatel D, Bout DT, Kasper LH: Gut-derived intraepithelial lymphocytes induce long term immunity against *Toxoplasma gondii*. *Journal of immunology* 1998, 161(9):4902-4908.
40. Inagaki-Ohara K, Dewi FN, Hisaeda H, Smith AL, Jimi F, Miyahira M, Abdel-Aleem AS, Horii Y, Nawa Y: Intestinal intraepithelial lymphocytes sustain the epithelial barrier function against *Eimeria vermiformis* infection. *Infection and immunity* 2006, 74(9):5292-5301.
41. Poussier P, Ning T, Banerjee D, Julius M: A unique subset of self-specific intrainestinal T cells maintains gut integrity. *The Journal of experimental medicine* 2002, 195(11):1491-1497.
42. Bhagat G, Naiyer AJ, Shah JG, Harper J, Jabri B, Wang TC, Green PH, Manavalan JS: Small intestinal CD8+TCR $\gamma\delta$ +NKG2A+ intraepithelial lymphocytes have attributes of regulatory cells in patients with celiac disease. *The Journal of clinical investigation* 2008, 118(1):281-293.
43. Strid J, Sobolev O, Zafirova B, Polic B, Hayday A: The intraepithelial T cell response to NKG2D-ligands links lymphoid stress surveillance to atopy. *Science* 2011, 334(6060):1293-1297.
44. Simpson SJ, Hollander GA, Mizoguchi E, Allen D, Bhan AK, Wang B, Terhorst C: Expression of pro-inflammatory cytokines by TCR $\alpha\beta$ + and TCR  $\gamma\delta$ + T cells in an experimental model of colitis. *European journal of immunology* 1997, 27(1):17-25.
45. Kanazawa H, Ishiguro Y, Munakata A, Morita T: Multiple accumulation of V $\delta$ 2+  $\gamma\delta$  T-cell clonotypes in intestinal mucosa from patients with Crohn's disease. *Digestive diseases and sciences* 2001, 46(2):410-416.
46. Yeung MM, Melgar S, Baranov V, Oberg A, Danielsson A, Hammarstrom S, Hammarstrom ML: Characterisation of mucosal lymphoid aggregates in ulcerative colitis: immune cell phenotype and TCR- $\gamma\delta$  expression. *Gut* 2000, 47(2):215-227.
47. Park SG, Mathur R, Long M, Hosh N, Hao L, Hayden MS, Ghosh S: T regulatory cells maintain intestinal homeostasis by suppressing  $\gamma\delta$  T cells. *Immunity* 2010, 33(5):791-803.
48. Meresse B, Chen Z, Ciszewski C, Tretiakova M, Bhagat G, Krausz TN, Raulet DH, Lanier LL, Groh V, Spies T *et al*: Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. *Immunity* 2004, 21(3):357-366.

49. Hirano M, Guo P, McCurley N, Schorpp M, Das S, Boehm T, Cooper MD: Evolutionary implications of a third lymphocyte lineage in lampreys. *Nature* 2013, 501(7467):435-438.
50. Hayday AC:  $\gamma\delta$  cells: a right time and a right place for a conserved third way of protection. *Annual review of immunology* 2000, 18:975-1026.
51. Carding SR, Egan PJ:  $\gamma\delta$  T cells: functional plasticity and heterogeneity. *Nature reviews Immunology* 2002, 2(5):336-345.
52. Bonneville M, O'Brien RL, Born WK:  $\gamma\delta$  T cell effector functions: a blend of innate programming and acquired plasticity. *Nature reviews Immunology* 2010, 10(7):467-478.
53. Asarnow DM, Kuziel WA, Bonyhadi M, Tigelaar RE, Tucker PW, Allison JP: Limited diversity of  $\gamma\delta$  antigen receptor genes of Thy-1+ dendritic epidermal cells. *Cell* 1988, 55(5):837-847.
54. Itohara S, Farr AG, Lafaille JJ, Bonneville M, Takagaki Y, Haas W, Tonegawa S: Homing of a  $\gamma\delta$  thymocyte subset with homogeneous T-cell receptors to mucosal epithelia. *Nature* 1990, 343(6260):754-757.
55. Havran WL, Jameson JM: Epidermal T cells and wound healing. *Journal of immunology* 2010, 184(10):5423-5428.
56. Pereira P, Lafaille JJ, Gerber D, Tonegawa S: The T cell receptor repertoire of intestinal intraepithelial  $\gamma\delta$  T lymphocytes is influenced by genes linked to the major histocompatibility complex and to the T cell receptor loci. *Proceedings of the National Academy of Sciences of the United States of America* 1997, 94(11):5761-5766.
57. Pennington DJ, Silva-Santos B, Hayday AC:  $\gamma\delta$  T cell development - having the strength to get there. *Current opinion in immunology* 2005, 17(2):108-115.
58. Dimova T, Brouwer M, Gosselin F, Tassignon J, Leo O, Donner C, Marchant A, Vermijlen D: Effector V $\gamma$ 9V $\delta$ 2 T cells dominate the human fetal  $\gamma\delta$  T-cell repertoire. *Proceedings of the National Academy of Sciences of the United States of America* 2015, 112(6):E556-565.
59. Heilig JS, Tonegawa S: Diversity of murine  $\gamma$  genes and expression in fetal and adult T lymphocytes. *Nature* 1986, 322(6082):836-840.
60. Lefranc MP, Rabbitts TH: A nomenclature to fit the organization of the human T-cell receptor  $\gamma$  and  $\delta$  genes. *Research in immunology* 1990, 141(7):615-618.
61. Prinz I, Silva-Santos B, Pennington DJ: Functional development of  $\gamma\delta$  T cells. *European journal of immunology* 2013, 43(8):1988-1994.
62. Vantourout P, Hayday A: Six-of-the-best: unique contributions of  $\gamma\delta$  T cells to immunology. *Nature reviews Immunology* 2013, 13(2):88-100.

## References

---

63. Silva-Santos B, Serre K, Norell H:  $\gamma\delta$  T cells in cancer. *Nature reviews Immunology* 2015, 15(11):683-691.
64. Serre K, Silva-Santos B: Molecular Mechanisms of Differentiation of Murine Pro-Inflammatory  $\gamma\delta$  T Cell Subsets. *Frontiers in immunology* 2013, 4:431.
65. Schmolka N, Wencker M, Hayday AC, Silva-Santos B: Epigenetic and transcriptional regulation of  $\gamma\delta$  T cell differentiation: Programming cells for responses in time and space. *Seminars in immunology* 2015, 27(1):19-25.
66. Conti L, Casetti R, Cardone M, Varano B, Martino A, Belardelli F, Poccia F, Gessani S: Reciprocal activating interaction between dendritic cells and pamidronate-stimulated  $\gamma\delta$  T cells: role of CD86 and inflammatory cytokines. *Journal of immunology* 2005, 174(1):252-260.
67. Caccamo N, Sireci G, Meraviglia S, Dieli F, Ivanyi J, Salerno A:  $\gamma\delta$  T cells condition dendritic cells *in vivo* for priming pulmonary CD8 T cell responses against *Mycobacterium tuberculosis*. *European journal of immunology* 2006, 36(10):2681-2690.
68. Devilder MC, Maillet S, Bouyge-Moreau I, Donnadiou E, Bonneville M, Scotet E: Potentiation of antigen-stimulated V $\gamma$ 9V $\delta$ 2 T cell cytokine production by immature dendritic cells (DC) and reciprocal effect on DC maturation. *Journal of immunology* 2006, 176(3):1386-1393.
69. Wen L, Pao W, Wong FS, Peng Q, Craft J, Zheng B, Kelsoe G, Dianda L, Owen MJ, Hayday AC: Germinal center formation, immunoglobulin class switching, and autoantibody production driven by "non  $\alpha\beta$ " T cells. *The Journal of experimental medicine* 1996, 183(5):2271-2282.
70. Ansel KM, Ngo VN, Hyman PL, Luther SA, Forster R, Sedgwick JD, Browning JL, Lipp M, Cyster JG: A chemokine-driven positive feedback loop organizes lymphoid follicles. *Nature* 2000, 406(6793):309-314.
71. Brandes M, Willimann K, Moser B: Professional antigen-presentation function by human  $\gamma\delta$  T Cells. *Science* 2005, 309(5732):264-268.
72. Brandes M, Willimann K, Bioley G, Levy N, Eberl M, Luo M, Tampe R, Levy F, Romero P, Moser B: Cross-presenting human  $\gamma\delta$  T cells induce robust CD8+  $\alpha\beta$  T cell responses. *Proceedings of the National Academy of Sciences of the United States of America* 2009, 106(7):2307-2312.
73. Himoudi N, Morgenstern DA, Yan M, Vernay B, Saraiva L, Wu Y, Cohen CJ, Gustafsson K, Anderson J: Human  $\gamma\delta$  T lymphocytes are licensed for professional antigen presentation by interaction with opsonized target cells. *Journal of immunology* 2012, 188(4):1708-1716.
74. Gao Y, Yang W, Pan M, Scully E, Girardi M, Augenlicht LH, Craft J, Yin Z:  $\gamma\delta$  T cells provide an early source of interferon  $\gamma$  in tumor immunity. *The Journal of experimental medicine* 2003, 198(3):433-442.



75. Liu Z, Eltoum IE, Guo B, Beck BH, Cloud GA, Lopez RD: Protective immunosurveillance and therapeutic antitumor activity of  $\gamma\delta$  T cells demonstrated in a mouse model of prostate cancer. *Journal of immunology* 2008, 180(9):6044-6053.
76. Lo Presti E, Dieli F, Meraviglia S: Tumor-Infiltrating  $\gamma\delta$  T Lymphocytes: Pathogenic Role, Clinical Significance, and Differential Programming in the Tumor Microenvironment. *Frontiers in immunology* 2014, 5:607.
77. Devaud C, Rousseau B, Netzer S, Pitard V, Paroissin C, Khairallah C, Costet P, Moreau JF, Couillaud F, Dechanet-Merville J *et al*: Anti-metastatic potential of human V $\delta$ 1+  $\gamma\delta$  T cells in an orthotopic mouse xenograft model of colon carcinoma. *Cancer immunology, immunotherapy : CII* 2013, 62(7):1199-1210.
78. Wu D, Wu P, Wu X, Ye J, Wang Z, Zhao S, Ni C, Hu G, Xu J, Han Y *et al*: *Ex vivo* expanded human circulating V $\delta$ 1  $\gamma\delta$  T cells exhibit favorable therapeutic potential for colon cancer. *Oncoimmunology* 2015, 4(3):e992749.
79. Ma S, Cheng Q, Cai Y, Gong H, Wu Y, Yu X, Shi L, Wu D, Dong C, Liu H: IL-17A produced by  $\gamma\delta$  T cells promotes tumor growth in hepatocellular carcinoma. *Cancer research* 2014, 74(7):1969-1982.
80. Coffelt SB, Kersten K, Doornebal CW, Weiden J, Vrijland K, Hau CS, Versteegen NJ, Ciampicotti M, Hawinkels LJ, Jonkers J *et al*: IL-17-producing  $\gamma\delta$  T cells and neutrophils conspire to promote breast cancer metastasis. *Nature* 2015, 522(7556):345-348.
81. Hao J, Dong S, Xia S, He W, Jia H, Zhang S, Wei J, O'Brien RL, Born WK, Wu Z *et al*: Regulatory role of V $\gamma$ 1  $\gamma\delta$  T cells in tumor immunity through IL-4 production. *Journal of immunology* 2011, 187(10):4979-4986.
82. Rei M, Pennington DJ, Silva-Santos B: The emerging Protumor role of  $\gamma\delta$  T lymphocytes: implications for cancer immunotherapy. *Cancer research* 2015, 75(5):798-802.
83. Silva-Santos B: Promoting angiogenesis within the tumor microenvironment: the secret life of murine lymphoid IL-17-producing  $\gamma\delta$  T cells. *European journal of immunology* 2010, 40(7):1873-1876.
84. Wu P, Wu D, Ni C, Ye J, Chen W, Hu G, Wang Z, Wang C, Zhang Z, Xia W *et al*:  $\gamma\delta$ T17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. *Immunity* 2014, 40(5):785-800.
85. Wakita D, Sumida K, Iwakura Y, Nishikawa H, Ohkuri T, Chamoto K, Kitamura H, Nishimura T: Tumor-infiltrating IL-17-producing  $\gamma\delta$  T cells support the progression of tumor by promoting angiogenesis. *European journal of immunology* 2010, 40(7):1927-1937.
86. Komano H, Fujiura Y, Kawaguchi M, Matsumoto S, Hashimoto Y, Obana S, Mombaerts P, Tonegawa S, Yamamoto H, Itohara S *et al*: Homeostatic

## References

---

- regulation of intestinal epithelia by intraepithelial  $\gamma\delta$  T cells. *Proceedings of the National Academy of Sciences of the United States of America* 1995, 92(13):6147-6151.
87. Groh V, Steinle A, Bauer S, Spies T: Recognition of stress-induced MHC molecules by intestinal epithelial  $\gamma\delta$  T cells. *Science* 1998, 279(5357):1737-1740.
  88. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T: Broad tumor-associated expression and recognition by tumor-derived  $\gamma\delta$  T cells of MICA and MICB. *Proceedings of the National Academy of Sciences of the United States of America* 1999, 96(12):6879-6884.
  89. Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, Hobby P, Sutton B, Tigelaar RE, Hayday AC: Regulation of cutaneous malignancy by  $\gamma\delta$  T cells. *Science* 2001, 294(5542):605-609.
  90. Jameson J, Ugarte K, Chen N, Yachi P, Fuchs E, Boismenu R, Havran WL: A role for skin  $\gamma\delta$  T cells in wound repair. *Science* 2002, 296(5568):747-749.
  91. King DP, Hyde DM, Jackson KA, Novosad DM, Ellis TN, Putney L, Stovall MY, Van Winkle LS, Beaman BL, Ferrick DA: Cutting edge: protective response to pulmonary injury requires  $\gamma\delta$  T lymphocytes. *Journal of immunology* 1999, 162(9):5033-5036.
  92. Sharp LL, Jameson JM, Cauvi G, Havran WL: Dendritic epidermal T cells regulate skin homeostasis through local production of insulin-like growth factor 1. *Nature immunology* 2005, 6(1):73-79.
  93. Guy-Grand D, DiSanto JP, Henchoz P, Malassis-Seris M, Vassalli P: Small bowel enteropathy: role of intraepithelial lymphocytes and of cytokines (IL-12, IFN- $\gamma$ , TNF) in the induction of epithelial cell death and renewal. *European journal of immunology* 1998, 28(2):730-744.
  94. Sharp LL, Jameson JM, Witherden DA, Komori HK, Havran WL: Dendritic epidermal T-cell activation. *Critical reviews in immunology* 2005, 25(1):1-18.
  95. Boismenu R, Havran WL: Modulation of epithelial cell growth by intraepithelial  $\gamma\delta$  T cells. *Science* 1994, 266(5188):1253-1255.
  96. Boismenu R, Feng L, Xia YY, Chang JC, Havran WL: Chemokine expression by intraepithelial  $\gamma\delta$  T cells. Implications for the recruitment of inflammatory cells to damaged epithelia. *Journal of immunology* 1996, 157(3):985-992.
  97. Cai Y, Shen X, Ding C, Qi C, Li K, Li X, Jala VR, Zhang HG, Wang T, Zheng J *et al*: Pivotal role of dermal IL-17-producing  $\gamma\delta$  T cells in skin inflammation. *Immunity* 2011, 35(4):596-610.
  98. Maki K, Sunaga S, Komagata Y, Kodaira Y, Mabuchi A, Karasuyama H, Yokomuro K, Miyazaki JI, Ikuta K: Interleukin 7 receptor-deficient mice lack  $\gamma\delta$  T cells. *Proceedings of the National Academy of Sciences of the United States of America* 1996, 93(14):7172-7177.

99. Kang J, Coles M, Raulat DH: Defective development of  $\gamma\delta$  T cells in interleukin 7 receptor-deficient mice is due to impaired expression of T cell receptor  $\gamma$  genes. *The Journal of experimental medicine* 1999, 190(7):973-982.
100. De Creus A, Van Beneden K, Stevenaert F, Debacker V, Plum J, Leclercq G: Developmental and functional defects of thymic and epidermal V $\gamma$ 3 cells in IL-15-deficient and IFN regulatory factor-1-deficient mice. *Journal of immunology* 2002, 168(12):6486-6493.
101. Baccala R, Witherden D, Gonzalez-Quintal R, Dummer W, Surh CD, Havran WL, Theofilopoulos AN:  $\gamma\delta$  T cell homeostasis is controlled by IL-7 and IL-15 together with subset-specific factors. *Journal of immunology* 2005, 174(8):4606-4612.
102. Sumaria N, Roediger B, Ng LG, Qin J, Pinto R, Cavanagh LL, Shklovskaya E, Fazekas de St Groth B, Triccas JA, Weninger W: Cutaneous immunosurveillance by self-renewing dermal  $\gamma\delta$  T cells. *The Journal of experimental medicine* 2011, 208(3):505-518.
103. Zhao H, Nguyen H, Kang J: Interleukin 15 controls the generation of the restricted T cell receptor repertoire of  $\gamma\delta$  intestinal intraepithelial lymphocytes. *Nature immunology* 2005, 6(12):1263-1271.
104. Pennington DJ, Silva-Santos B, Shires J, Theodoridis E, Pollitt C, Wise EL, Tigelaar RE, Owen MJ, Hayday AC: The inter-relatedness and interdependence of mouse T cell receptor  $\gamma\delta$ + and  $\alpha\beta$ + cells. *Nature immunology* 2003, 4(10):991-998.
105. Witherden DA, Havran WL: Cross-talk between intraepithelial  $\gamma\delta$  T cells and epithelial cells. *Journal of leukocyte biology* 2013, 94(1):69-76.
106. Havran WL, Jameson JM, Witherden DA: Epithelial cells and their neighbors. III. Interactions between intraepithelial lymphocytes and neighboring epithelial cells. *American journal of physiology Gastrointestinal and liver physiology* 2005, 289(4):G627-630.
107. Raulat DH: Roles of the NKG2D immunoreceptor and its ligands. *Nature reviews Immunology* 2003, 3(10):781-790.
108. Champsaur M, Lanier LL: Effect of NKG2D ligand expression on host immune responses. *Immunol Rev* 2010, 235(1):267-285.
109. Eagle RA, Trowsdale J: Promiscuity and the single receptor: NKG2D. *Nature reviews Immunology* 2007, 7(9):737-744.
110. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T: Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. *Science* 1999, 285(5428):727-729.
111. Nitahara A, Shimura H, Ito A, Tomiyama K, Ito M, Kawai K: NKG2D ligation without T cell receptor engagement triggers both cytotoxicity and

## References

---

- cytokine production in dendritic epidermal T cells. *The Journal of investigative dermatology* 2006, 126(5):1052-1058.
112. Whang MI, Guerra N, Raulet DH: Costimulation of dendritic epidermal  $\gamma\delta$  T cells by a new NKG2D ligand expressed specifically in the skin. *Journal of immunology* 2009, 182(8):4557-4564.
113. Yoshida S, Mohamed RH, Kajikawa M, Koizumi J, Tanaka M, Fugo K, Otsuka N, Maenaka K, Yagita H, Chiba H *et al.*: Involvement of an NKG2D ligand H60c in epidermal dendritic T cell-mediated wound repair. *Journal of immunology* 2012, 188(8):3972-3979.
114. Moog-Lutz C, Cave-Riant F, Guibal FC, Breau MA, Di Gioia Y, Couraud PO, Cayre YE, Bourdoulous S, Lutz PG: JAML, a novel protein with characteristics of a junctional adhesion molecule, is induced during differentiation of myeloid leukemia cells. *Blood* 2003, 102(9):3371-3378.
115. Witherden DA, Verdino P, Rieder SE, Garijo O, Mills RE, Teyton L, Fischer WH, Wilson IA, Havran WL: The junctional adhesion molecule JAML is a costimulatory receptor for epithelial  $\gamma\delta$  T cell activation. *Science* 2010, 329(5996):1205-1210.
116. Zen K, Liu Y, McCall IC, Wu T, Lee W, Babbitt BA, Nusrat A, Parkos CA: Neutrophil migration across tight junctions is mediated by adhesive interactions between epithelial coxsackie and adenovirus receptor and a junctional adhesion molecule-like protein on neutrophils. *Molecular biology of the cell* 2005, 16(6):2694-2703.
117. Verdino P, Witherden DA, Havran WL, Wilson IA: The molecular interaction of CAR and JAML recruits the central cell signal transducer PI3K. *Science* 2010, 329(5996):1210-1214.
118. Kumanogoh A, Kikutani H: Semaphorins and their receptors: novel features of neural guidance molecules. *Proceedings of the Japan Academy Series B, Physical and biological sciences* 2010, 86(6):611-620.
119. Shi W, Kumanogoh A, Watanabe C, Uchida J, Wang X, Yasui T, Yukawa K, Ikawa M, Okabe M, Parnes JR *et al.*: The class IV semaphorin CD100 plays nonredundant roles in the immune system: defective B and T cell activation in CD100-deficient mice. *Immunity* 2000, 13(5):633-642.
120. Witherden DA, Watanabe M, Garijo O, Rieder SE, Sarkisyan G, Cronin SJ, Verdino P, Wilson IA, Kumanogoh A, Kikutani H *et al.*: The CD100 receptor interacts with its plexin B2 ligand to regulate epidermal  $\gamma\delta$  T cell function. *Immunity* 2012, 37(2):314-325.
121. Meehan TF, Witherden DA, Kim CH, Sendaydiego K, Ye I, Garijo O, Komori HK, Kumanogoh A, Kikutani H, Eckmann L *et al.*: Protection against colitis by CD100-dependent modulation of intraepithelial  $\gamma\delta$  T lymphocyte function. *Mucosal immunology* 2014, 7(1):134-142.

122. Boyden LM, Lewis JM, Barbee SD, Bas A, Girardi M, Hayday AC, Tigelaar RE, Lifton RP: Skint1, the prototype of a newly identified immunoglobulin superfamily gene cluster, positively selects epidermal  $\gamma\delta$  T cells. *Nature genetics* 2008, 40(5):656-662.
123. Lewis JM, Girardi M, Roberts SJ, Barbee SD, Hayday AC, Tigelaar RE: Selection of the cutaneous intraepithelial  $\gamma\delta^+$  T cell repertoire by a thymic stromal determinant. *Nature immunology* 2006, 7(8):843-850.
124. Barbee SD, Woodward MJ, Turchinovich G, Mention JJ, Lewis JM, Boyden LM, Lifton RP, Tigelaar R, Hayday AC: Skint-1 is a highly specific, unique selecting component for epidermal T cells. *Proceedings of the National Academy of Sciences of the United States of America* 2011, 108(8):3330-3335.
125. Turchinovich G, Hayday AC: Skint-1 identifies a common molecular mechanism for the development of interferon- $\gamma$ -secreting versus interleukin-17-secreting  $\gamma\delta$  T cells. *Immunity* 2011, 35(1):59-68.
126. Abeler-Dorner L, Swamy M, Williams G, Hayday AC, Bas A: Butyrophilins: an emerging family of immune regulators. *Trends in immunology* 2012, 33(1):34-41.
127. Arnett HA, Escobar SS, Viney JL: Regulation of costimulation in the era of butyrophilins. *Cytokine* 2009, 46(3):370-375.
128. Arnett HA, Viney JL: Immune modulation by butyrophilins. *Nature reviews Immunology* 2014, 14(8):559-569.
129. Rhodes DA, Reith W, Trowsdale J: Regulation of Immunity by Butyrophilins. *Annual review of immunology* 2016.
130. Afrache H, Gouret P, Ainouche S, Pontarotti P, Olive D: The butyrophilin (BTN) gene family: from milk fat to the regulation of the immune response. *Immunogenetics* 2012, 64(11):781-794.
131. Chen L, Flies DB: Molecular mechanisms of T cell co-stimulation and co-inhibition. *Nature reviews Immunology* 2013, 13(4):227-242.
132. Coyle AJ, Gutierrez-Ramos JC: The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. *Nature immunology* 2001, 2(3):203-209.
133. Sharpe AH, Freeman GJ: The B7-CD28 superfamily. *Nature reviews Immunology* 2002, 2(2):116-126.
134. Compte E, Pontarotti P, Collette Y, Lopez M, Olive D: Frontline: Characterization of BT3 molecules belonging to the B7 family expressed on immune cells. *European journal of immunology* 2004, 34(8):2089-2099.
135. Stammers M, Rowen L, Rhodes D, Trowsdale J, Beck S: BTL-II: a polymorphic locus with homology to the butyrophilin gene family, located at the border of the major histocompatibility complex class II and class III regions in human and mouse. *Immunogenetics* 2000, 51(4-5):373-382.

## References

---

136. Rhodes DA, Stammers M, Malcherek G, Beck S, Trowsdale J: The cluster of BTN genes in the extended major histocompatibility complex. *Genomics* 2001, 71(3):351-362.
137. Ye TZ, Gordon CT, Lai YH, Fujiwara Y, Peters LL, Perkins AC, Chui DH: Ermap, a gene coding for a novel erythroid specific adhesion/receptor membrane protein. *Gene* 2000, 242(1-2):337-345.
138. Su YY, Gordon CT, Ye TZ, Perkins AC, Chui DH: Human ERMAP: an erythroid adhesion/receptor transmembrane protein. *Blood cells, molecules & diseases* 2001, 27(5):938-949.
139. Kroepfl JF, Viise LR, Charron AJ, Linington C, Gardinier MV: Investigation of myelin/oligodendrocyte glycoprotein membrane topology. *Journal of neurochemistry* 1996, 67(5):2219-2222.
140. Gardinier MV, Amiguet P, Linington C, Matthieu JM: Myelin/oligodendrocyte glycoprotein is a unique member of the immunoglobulin superfamily. *Journal of neuroscience research* 1992, 33(1):177-187.
141. Bleoo S, Sun X, Hendzel MJ, Rowe JM, Packer M, Godbout R: Association of human DEAD box protein DDX1 with a cleavage stimulation factor involved in 3'-end processing of pre-mRNA. *Molecular biology of the cell* 2001, 12(10):3046-3059.
142. Schwarzmann N, Kunerth S, Weber K, Mayr GW, Guse AH: Knock-down of the type 3 ryanodine receptor impairs sustained Ca<sup>2+</sup> signaling via the T cell receptor/CD3 complex. *The Journal of biological chemistry* 2002, 277(52):50636-50642.
143. Adamson AL, Shearn A: Molecular genetic analysis of *Drosophila* ash2, a member of the trithorax group required for imaginal disc pattern formation. *Genetics* 1996, 144(2):621-633.
144. Rosa JL, Barbacid M: A giant protein that stimulates guanine nucleotide exchange on ARF1 and Rab proteins forms a cytosolic ternary complex with clathrin and Hsp70. *Oncogene* 1997, 15(1):1-6.
145. Kile BT, Alexander WS: The suppressors of cytokine signalling (SOCS). *Cellular and molecular life sciences : CMLS* 2001, 58(11):1627-1635.
146. Rhodes DA, de Bono B, Trowsdale J: Relationship between SPRY and B30.2 protein domains. Evolution of a component of immune defence? *Immunology* 2005, 116(4):411-417.
147. D'Cruz AA, Babon JJ, Norton RS, Nicola NA, Nicholson SE: Structure and function of the SPRY/B30.2 domain proteins involved in innate immunity. *Protein science : a publication of the Protein Society* 2013, 22(1):1-10.

148. Mische CC, Javanbakht H, Song B, Diaz-Griffero F, Stremlau M, Strack B, Si Z, Sodroski J: Retroviral restriction factor TRIM5 $\alpha$  is a trimer. *Journal of virology* 2005, 79(22):14446-14450.
149. Rhodes DA, Trowsdale J: TRIM21 is a trimeric protein that binds IgG Fc via the B30.2 domain. *Molecular immunology* 2007, 44(9):2406-2414.
150. Woo JS, Imm JH, Min CK, Kim KJ, Cha SS, Oh BH: Structural and functional insights into the B30.2/SPRY domain. *The EMBO journal* 2006, 25(6):1353-1363.
151. Bas A, Swamy M, Abeler-Dorner L, Williams G, Pang DJ, Barbee SD, Hayday AC: Butyrophilin-like 1 encodes an enterocyte protein that selectively regulates functional interactions with T lymphocytes. *Proceedings of the National Academy of Sciences of the United States of America* 2011, 108(11):4376-4381.
152. Malcherek G, Mayr L, Roda-Navarro P, Rhodes D, Miller N, Trowsdale J: The B7 homolog butyrophilin BTN2A1 is a novel ligand for DC-SIGN. *Journal of immunology* 2007, 179(6):3804-3811.
153. Smith IA, Knezevic BR, Ammann JU, Rhodes DA, Aw D, Palmer DB, Mather IH, Trowsdale J: BTN1A1, the mammary gland butyrophilin, and BTN2A2 are both inhibitors of T cell activation. *Journal of immunology* 2010, 184(7):3514-3525.
154. Valentonyte R, Hampe J, Huse K, Rosenstiel P, Albrecht M, Stenzel A, Nagy M, Gaede KI, Franke A, Haesler R *et al*: Sarcoidosis is associated with a truncating splice site mutation in BTNL2. *Nature genetics* 2005, 37(4):357-364.
155. Rybicki BA, Walewski JL, Maliarik MJ, Kian H, Iannuzzi MC, Group AR: The BTNL2 gene and sarcoidosis susceptibility in African Americans and Whites. *American journal of human genetics* 2005, 77(3):491-499.
156. Li Y, Wollnik B, Pabst S, Lennarz M, Rohmann E, Gillissen A, Vetter H, Grohe C: BTNL2 gene variant and sarcoidosis. *Thorax* 2006, 61(3):273-274.
157. Spagnolo P, Sato H, Grutters JC, Renzoni EA, Marshall SE, Ruven HJ, Wells AU, Tzouveleki A, van Moorsel CH, van den Bosch JM *et al*: Analysis of BTNL2 genetic polymorphisms in British and Dutch patients with sarcoidosis. *Tissue antigens* 2007, 70(3):219-227.
158. Li Y, Pabst S, Lokhande S, Grohe C, Wollnik B: Extended genetic analysis of BTNL2 in sarcoidosis. *Tissue antigens* 2009, 73(1):59-61.
159. Wijnen PA, Voorter CE, Nelemans PJ, Verschakelen JA, Bekers O, Drent M: Butyrophilin-like 2 in pulmonary sarcoidosis: a factor for susceptibility and progression? *Human immunology* 2011, 72(4):342-347.
160. Morais A, Lima B, Peixoto MJ, Alves H, Marques A, Delgado L: BTNL2 gene polymorphism associations with susceptibility and phenotype expression in sarcoidosis. *Respiratory medicine* 2012, 106(12):1771-1777.

## References

---

161. Suzuki H, Ota M, Meguro A, Katsuyama Y, Kawagoe T, Ishihara M, Asukata Y, Takeuchi M, Ito N, Shibuya E *et al*: Genetic characterization and susceptibility for sarcoidosis in Japanese patients: risk factors of BTNL2 gene polymorphisms and HLA class II alleles. *Investigative ophthalmology & visual science* 2012, 53(11):7109-7115.
162. Gaillot-Drevon M, Calender A, Blay JY, Valeyre D, Israel-Biet D, Roy P, Pacheco Y: Lack of correlation of BTNL2 polymorphism and cancer risk in sarcoidosis. BTNL2 and cancer risk in sarcoidosis. *Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG / World Association of Sarcoidosis and Other Granulomatous Disorders* 2014, 31(2):136-141.
163. Lin Y, Wei J, Fan L, Cheng D: BTNL2 gene polymorphism and sarcoidosis susceptibility: a meta-analysis. *PLoS one* 2015, 10(4):e0122639.
164. Mochida A, Kinouchi Y, Negoro K, Takahashi S, Takagi S, Nomura E, Kakuta Y, Tosa M, Shimosegawa T: Butyrophilin-like 2 gene is associated with ulcerative colitis in the Japanese under strong linkage disequilibrium with HLA-DRB1\*1502. *Tissue antigens* 2007, 70(2):128-135.
165. Pathan S, Gowdy RE, Cooney R, Beckly JB, Hancock L, Guo C, Barrett JC, Morris A, Jewell DP: Confirmation of the novel association at the BTNL2 locus with ulcerative colitis. *Tissue antigens* 2009, 74(4):322-329.
166. Johnson CM, Traherne JA, Jamieson SE, Tremelling M, Bingham S, Parkes M, Blackwell JM, Trowsdale J: Analysis of the BTNL2 truncating splice site mutation in tuberculosis, leprosy and Crohn's disease. *Tissue antigens* 2007, 69(3):236-241.
167. Orozco G, Eerligh P, Sanchez E, Zhernakova S, Roep BO, Gonzalez-Gay MA, Lopez-Nevot MA, Callejas JL, Hidalgo C, Pascual-Salcedo D *et al*: Analysis of a functional BTNL2 polymorphism in type 1 diabetes, rheumatoid arthritis, and systemic lupus erythematosus. *Human immunology* 2005, 66(12):1235-1241.
168. Mitsunaga S, Hosomichi K, Okudaira Y, Nakaoka H, Kunii N, Suzuki Y, Kuwana M, Sato S, Kaneko Y, Homma Y *et al*: Exome sequencing identifies novel rheumatoid arthritis-susceptible variants in the BTNL2. *Journal of human genetics* 2013, 58(4):210-215.
169. Price P, Santoso L, Mastaglia F, Garlepp M, Kok CC, Allcock R, Laing N: Two major histocompatibility complex haplotypes influence susceptibility to sporadic inclusion body myositis: critical evaluation of an association with HLA-DR3. *Tissue antigens* 2004, 64(5):575-580.
170. Moller M, Kwiatkowski R, Nebel A, van Helden PD, Hoal EG, Schreiber S: Allelic variation in BTNL2 and susceptibility to tuberculosis in a South African population. *Microbes and infection / Institut Pasteur* 2007, 9(4):522-528.
171. Lian Y, Yue J, Han M, Liu J, Liu L: Analysis of the association between BTNL2 polymorphism and tuberculosis in Chinese Han population. *Infection*,



- genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases* 2010, 10(4):517-521.
172. Konno S, Takahashi D, Hizawa N, Hattori T, Takahashi A, Isada A, Maeda Y, Huang SK, Nishimura M: Genetic impact of a butyrophilin-like 2 (BTNL2) gene variation on specific IgE responsiveness to *Dermatophagoides farinae* (*Der f*) in Japanese. *Allergy international : official journal of the Japanese Society of Allergy* 2009, 58(1):29-35.
  173. Fitzgerald LM, Kumar A, Boyle EA, Zhang Y, McIntosh LM, Kolb S, Stott-Miller M, Smith T, Karyadi DM, Ostrander EA *et al*: Germline missense variants in the BTNL2 gene are associated with prostate cancer susceptibility. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology* 2013, 22(9):1520-1528.
  174. Cubillos-Ruiz JR, Martinez D, Scarlett UK, Rutkowski MR, Nesbeth YC, Camposeco-Jacobs AL, Conejo-Garcia JR: CD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells. *Oncotarget* 2010, 1(5):329-338.
  175. Peedicayil A, Vierkant RA, Hartmann LC, Fridley BL, Fredericksen ZS, White KL, Elliott EA, Phelan CM, Tsai YY, Berchuck A *et al*: Risk of ovarian cancer and inherited variants in relapse-associated genes. *PLoS one* 2010, 5(1):e8884.
  176. Le Page C, Marineau A, Bonza PK, Rahimi K, Cyr L, Labouba I, Madore J, Delvoe N, Mes-Masson AM, Provencher DM *et al*: BTN3A2 expression in epithelial ovarian cancer is associated with higher tumor infiltrating T cells and a better prognosis. *PLoS one* 2012, 7(6):e38541.
  177. Viken MK, Blomhoff A, Olsson M, Akselsen HE, Pociot F, Nerup J, Kockum I, Cambon-Thomsen A, Thorsby E, Undlien DE *et al*: Reproducible association with type 1 diabetes in the extended class I region of the major histocompatibility complex. *Genes and immunity* 2009, 10(4):323-333.
  178. Hiramatsu M, Oguri M, Kato K, Horibe H, Fujimaki T, Watanabe S, Satoh K, Aoyagi Y, Tanaka M, Shin DJ *et al*: Synergistic effects of genetic variants of APOA5 and BTN2A1 on dyslipidemia or metabolic syndrome. *International journal of molecular medicine* 2012, 30(1):185-192.
  179. Fujimaki T, Kato K, Oguri M, Yohida T, Horibe H, Yokoi K, Watanabe S, Satoh K, Aoyagi Y, Tanaka M *et al*: Association of a polymorphism of BTN2A1 with dyslipidemia in East Asian populations. *Experimental and therapeutic medicine* 2011, 2(4):745-749.
  180. Horibe H, Ueyama C, Fujimaki T, Oguri M, Kato K, Ichihara S, Yamada Y: Association of a polymorphism of BTN2A1 with dyslipidemia in community-dwelling individuals. *Molecular medicine reports* 2014, 9(3):808-812.

## References

---

181. Yamada Y, Nishida T, Ichihara S, Sawabe M, Fuku N, Nishigaki Y, Aoyagi Y, Tanaka M, Fujiwara Y, Yoshida H *et al*: Association of a polymorphism of BTN2A1 with myocardial infarction in East Asian populations. *Atherosclerosis* 2011, 215(1):145-152.
182. Yoshida T, Kato K, Oguri M, Horibe H, Kawamiya T, Yokoi K, Fujimaki T, Watanabe S, Satoh K, Aoyagi Y *et al*: Association of polymorphisms of BTN2A1 and ILF3 with myocardial infarction in Japanese individuals with different lipid profiles. *Molecular medicine reports* 2011, 4(3):511-518.
183. Murakata Y, Fujimaki T, Yamada Y: Association of a butyrophilin, subfamily 2, member A1 gene polymorphism with hypertension. *Biomedical reports* 2014, 2(6):818-822.
184. Garcia-Vallejo JJ, Ilarregui JM, Kalay H, Chamorro S, Koning N, Unger WW, Ambrosini M, Montserrat V, Fernandes RJ, Bruijns SC *et al*: CNS myelin induces regulatory functions of DC-SIGN-expressing, antigen-presenting cells via cognate interaction with MOG. *The Journal of experimental medicine* 2014, 211(7):1465-1483.
185. Messal N, Mamessier E, Sylvain A, Celis-Gutierrez J, Thibult ML, Chetaille B, Firaguay G, Pastor S, Guillaume Y, Wang Q *et al*: Differential role for CD277 as a co-regulator of the immune signal in T and NK cells. *European journal of immunology* 2011, 41(12):3443-3454.
186. Yamashiro H, Yoshizaki S, Tadaki T, Egawa K, Seo N: Stimulation of human butyrophilin 3 molecules results in negative regulation of cellular immunity. *Journal of leukocyte biology* 2010, 88(4):757-767.
187. Palakodeti A, Sandstrom A, Sundaresan L, Harly C, Nedellec S, Olive D, Scotet E, Bonneville M, Adams EJ: The molecular basis for modulation of human V $\gamma$ 9V $\delta$ 2 T cell responses by CD277/butyrophilin-3 (BTN3A)-specific antibodies. *The Journal of biological chemistry* 2012, 287(39):32780-32790.
188. Wang H, Henry O, Distefano MD, Wang YC, Raikkonen J, Monkkonen J, Tanaka Y, Morita CT: Butyrophilin 3A1 plays an essential role in prenyl pyrophosphate stimulation of human V $\gamma$ 2V $\delta$ 2 T cells. *Journal of immunology* 2013, 191(3):1029-1042.
189. Vavassori S, Kumar A, Wan GS, Ramanjaneyulu GS, Cavallari M, El Daker S, Beddoe T, Theodossis A, Williams NK, Gostick E *et al*: Butyrophilin 3A1 binds phosphorylated antigens and stimulates human  $\gamma\delta$  T cells. *Nature immunology* 2013, 14(9):908-916.
190. Kabelitz D: Critical role of butyrophilin 3A1 in presenting prenyl pyrophosphate antigens to human  $\gamma\delta$  T cells. *Cellular & molecular immunology* 2014, 11(2):117-119.
191. Decaup E, Duault C, Bezombes C, Poupot M, Savina A, Olive D, Fournie JJ: Phosphoantigens and butyrophilin 3A1 induce similar intracellular activation

- signaling in human TCRV $\gamma$ 9+  $\gamma\delta$  T lymphocytes. *Immunology letters* 2014, 161(1):133-137.
192. Sandstrom A, Peigne CM, Leger A, Crooks JE, Konczak F, Gesnel MC, Breathnach R, Bonneville M, Scotet E, Adams EJ: The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human V $\gamma$ 9V $\delta$ 2 T cells. *Immunity* 2014, 40(4):490-500.
193. Wang H, Morita CT: Sensor Function for Butyrophilin 3A1 in Prenyl Pyrophosphate Stimulation of Human V $\gamma$ 2V $\delta$ 2 T Cells. *Journal of immunology* 2015, 195(10):4583-4594.
194. Chapoval AI, Smithson G, Brunick L, Mesri M, Boldog FL, Andrew D, Khramtsov NV, Feshchenko EA, Starling GC, Mezes PS: BTNL8, a butyrophilin-like molecule that costimulates the primary immune response. *Molecular immunology* 2013, 56(4):819-828.
195. Robenek H, Hofnagel O, Buers I, Lorkowski S, Schnoor M, Robenek MJ, Heid H, Troyer D, Severs NJ: Butyrophilin controls milk fat globule secretion. *Proceedings of the National Academy of Sciences of the United States of America* 2006, 103(27):10385-10390.
196. Ogg SL, Weldon AK, Dobbie L, Smith AJ, Mather IH: Expression of butyrophilin (Btn1a1) in lactating mammary gland is essential for the regulated secretion of milk-lipid droplets. *Proceedings of the National Academy of Sciences of the United States of America* 2004, 101(27):10084-10089.
197. Bernard CC, Johns TG, Slavin A, Ichikawa M, Ewing C, Liu J, Bettadapura J: Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis. *Journal of molecular medicine (Berlin, Germany)* 1997, 75(2):77-88.
198. Pagany M, Jagodic M, Bourquin C, Olsson T, Linington C: Genetic variation in myelin oligodendrocyte glycoprotein expression and susceptibility to experimental autoimmune encephalomyelitis. *Journal of neuroimmunology* 2003, 139(1-2):1-8.
199. Delarasse C, Daubas P, Mars LT, Vizler C, Litzenburger T, Iglesias A, Bauer J, Della Gaspera B, Schubart A, Decker L *et al*: Myelin/oligodendrocyte glycoprotein-deficient (MOG-deficient) mice reveal lack of immune tolerance to MOG in wild-type mice. *The Journal of clinical investigation* 2003, 112(4):544-553.
200. Guggenmos J, Schubart AS, Ogg S, Andersson M, Olsson T, Mather IH, Linington C: Antibody cross-reactivity between myelin oligodendrocyte glycoprotein and the milk protein butyrophilin in multiple sclerosis. *Journal of immunology* 2004, 172(1):661-668.
201. Stefferl A, Schubart A, Storch M, Amini A, Mather I, Lassmann H, Linington C: Butyrophilin, a milk protein, modulates the encephalitogenic T cell response

## References

---

- to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis. *Journal of immunology* 2000, 165(5):2859-2865.
202. Mana P, Goodyear M, Bernard C, Tomioka R, Freire-Garabal M, Linares D: Tolerance induction by molecular mimicry: prevention and suppression of experimental autoimmune encephalomyelitis with the milk protein butyrophilin. *International immunology* 2004, 16(3):489-499.
203. Ammann JU, Cooke A, Trowsdale J: Butyrophilin Btn2a2 inhibits TCR activation and phosphatidylinositol 3-kinase/Akt pathway signaling and induces Foxp3 expression in T lymphocytes. *Journal of immunology* 2013, 190(10):5030-5036.
204. Sarter K, Leimgruber E, Gobet F, Agrawal V, Dunand-Sauthier I, Barras E, Mastelic-Gavillet B, Kamath A, Fontannaz P, Guery L *et al*: Btn2a2, a T cell immunomodulatory molecule coregulated with MHC class II genes. *The Journal of experimental medicine* 2016.
205. Nguyen T, Liu XK, Zhang Y, Dong C: BTNL2, a butyrophilin-like molecule that functions to inhibit T cell activation. *Journal of immunology* 2006, 176(12):7354-7360.
206. Arnett HA, Escobar SS, Gonzalez-Suarez E, Budelsky AL, Steffen LA, Boiani N, Zhang M, Siu G, Brewer AW, Viney JL: BTNL2, a butyrophilin/B7-like molecule, is a negative costimulatory molecule modulated in intestinal inflammation. *Journal of immunology* 2007, 178(3):1523-1533.
207. Swanson RM, Gavin MA, Escobar SS, Rottman JB, Lipsky BP, Dube S, Li L, Bigler J, Wolfson M, Arnett HA *et al*: Butyrophilin-like 2 modulates B7 costimulation to induce Foxp3 expression and regulatory T cell development in mature T cells. *Journal of immunology* 2013, 190(5):2027-2035.
208. Yamazaki T, Goya I, Graf D, Craig S, Martin-Orozco N, Dong C: A butyrophilin family member critically inhibits T cell activation. *Journal of immunology* 2010, 185(10):5907-5914.
209. Dieli F, Fadda R, Caccamo N: Butyrophilin 3A1 presents phosphoantigens to human  $\gamma\delta$  T cells: the fourth model of antigen presentation in the immune system. *Cellular & molecular immunology* 2014, 11(2):123-125.
210. Hsiao CH, Lin X, Barney RJ, Shippy RR, Li J, Vinogradova O, Wiemer DF, Wiemer AJ: Synthesis of a phosphoantigen prodrug that potently activates V $\gamma$ 9V $\delta$ 2 T-lymphocytes. *Chemistry & biology* 2014, 21(8):945-954.
211. Johansson ME, Larsson JM, Hansson GC: The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. *Proceedings of the National Academy of Sciences of the United States of America* 2011, 108 Suppl 1:4659-4665.

212. Van der Sluis M, De Koning BA, De Bruijn AC, Velcich A, Meijerink JP, Van Goudoever JB, Buller HA, Dekker J, Van Seuningen I, Renes IB *et al*: Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. *Gastroenterology* 2006, 131(1):117-129.
213. Johansson ME, Gustafsson JK, Holmen-Larsson J, Jabbar KS, Xia L, Xu H, Ghishan FK, Carvalho FA, Gewirtz AT, Sjovall H *et al*: Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis. *Gut* 2014, 63(2):281-291.
214. Moser AR, Luongo C, Gould KA, McNeley MK, Shoemaker AR, Dove WF: Apc<sup>Min</sup>: a mouse model for intestinal and mammary tumorigenesis. *European journal of cancer (Oxford, England : 1990)* 1995, 31A(7-8):1061-1064.
215. Thompson MB: The Min mouse: a genetic model for intestinal carcinogenesis. *Toxicologic pathology* 1997, 25(3):329-332.
216. Graham FL, Smiley J, Russell WC, Nairn R: Characteristics of a human cell line transformed by DNA from human adenovirus type 5. *The Journal of general virology* 1977, 36(1):59-74.
217. Todaro GJ, Green H: Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines. *The Journal of cell biology* 1963, 17:299-313.
218. Vidal K, Grosjean I, Evillard JP, Gespach C, Kaiserlian D: Immortalization of mouse intestinal epithelial cells by the SV40-large T gene. Phenotypic and immune characterization of the MODE-K cell line. *Journal of immunological methods* 1993, 166(1):63-73.
219. Lundqvist C, Hammarstrom ML, Athlin L, Hammarstrom S: Isolation of functionally active intraepithelial lymphocytes and enterocytes from human small and large intestine. *Journal of immunological methods* 1992, 152(2):253-263.
220. Rahman A, Fahlgren A, Sundstedt C, Hammarstrom S, Danielsson A, Hammarstrom ML: Chronic colitis induces expression of  $\beta$ -defensins in murine intestinal epithelial cells. *Clinical and experimental immunology* 2011, 163(1):123-130.
221. Guy-Grand D, Griscelli C, Vassalli P: The mouse gut T lymphocyte, a novel type of T cell. Nature, origin, and traffic in mice in normal and graft-versus-host conditions. *The Journal of experimental medicine* 1978, 148(6):1661-1677.
222. Swamy M, Abeler-Dorner L, Chettle J, Mahlakoiv T, Goubau D, Chakravarty P, Ramsay G, Reis ESC, Staeheli P, Blacklaws BA *et al*: Intestinal intraepithelial lymphocyte activation promotes innate antiviral resistance. *Nature communications* 2015, 6:7090.
223. Lis H, Sharon N: Protein glycosylation. Structural and functional aspects. *European journal of biochemistry / FEBS* 1993, 218(1):1-27.

## References

---

224. Belkaid Y, Hand TW: Role of the microbiota in immunity and inflammation. *Cell* 2014, 157(1):121-141.
225. Viney JL, MacDonald TT: Selective death of T cell receptor  $\gamma\delta$ + intraepithelial lymphocytes by apoptosis. *European journal of immunology* 1990, 20(12):2809-2812.
226. Brunner T, Arnold D, Wasem C, Herren S, Frutschi C: Regulation of cell death and survival in intestinal intraepithelial lymphocytes. *Cell death and differentiation* 2001, 8(7):706-714.
227. Penney L, Kilshaw PJ, MacDonald TT: Regional variation in the proliferative rate and lifespan of  $\alpha\beta$  TCR+ and  $\gamma\delta$  TCR+ intraepithelial lymphocytes in the murine small intestine. *Immunology* 1995, 86(2):212-218.
228. Stankovic S, Zhan Y, Harrison LC: Homeostatic proliferation of intestinal intraepithelial lymphocytes precedes their migration to extra-intestinal sites. *European journal of immunology* 2007, 37(8):2226-2233.
229. Reinecker HC, MacDermott RP, Mirau S, Dignass A, Podolsky DK: Intestinal epithelial cells both express and respond to interleukin 15. *Gastroenterology* 1996, 111(6):1706-1713.
230. Lai YG, Gelfanov V, Gelfanova V, Kulik L, Chu CL, Jeng SW, Liao NS: IL-15 promotes survival but not effector function differentiation of CD8+ TCR $\alpha\beta$ + intestinal intraepithelial lymphocytes. *Journal of immunology* 1999, 163(11):5843-5850.
231. Inagaki-Ohara K, Nishimura H, Mitani A, Yoshikai Y: Interleukin-15 preferentially promotes the growth of intestinal intraepithelial lymphocytes bearing  $\gamma\delta$  T cell receptor in mice. *European journal of immunology* 1997, 27(11):2885-2891.
232. Boyman O, Kolios AG, Raeber ME: Modulation of T cell responses by IL-2 and IL-2 complexes. *Clinical and experimental rheumatology* 2015, 33(4 Suppl 92):S54-57.
233. Lefrancois L, LeCorre R, Mayo J, Bluestone JA, Goodman T: Extrathymic selection of TCR $\gamma\delta$ + T cells by class II major histocompatibility complex molecules. *Cell* 1990, 63(2):333-340.
234. Ohman L, Dahlen R, Isaksson S, Sjoling A, Wick MJ, Sjovall H, Van Oudenhove L, Simren M, Strid H: Serum IL-17A in newly diagnosed treatment-naïve patients with ulcerative colitis reflects clinical disease severity and predicts the course of disease. *Inflammatory bowel diseases* 2013, 19(11):2433-2439.
235. Bradesi S, McRoberts JA, Anton PA, Mayer EA: Inflammatory bowel disease and irritable bowel syndrome: separate or unified? *Current opinion in gastroenterology* 2003, 19(4):336-342.

- 
236. Wenzel UA, Magnusson MK, Rydstrom A, Jonstrand C, Hengst J, Johansson ME, Velcich A, Ohman L, Strid H, Sjovall H *et al*: Spontaneous colitis in Muc2-deficient mice reflects clinical and cellular features of active ulcerative colitis. *PLoS one* 2014, 9(6):e100217.
  237. Wenzel UA, Jonstrand C, Hansson GC, Wick MJ: CD103+ CD11b+ Dendritic Cells Induce Th17 T Cells in Muc2-Deficient Mice with Extensively Spread Colitis. *PLoS one* 2015, 10(6):e0130750.
  238. Kaplanski G, Marin V, Montero-Julian F, Mantovani A, Farnarier C: IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. *Trends in immunology* 2003, 24(1):25-29.
  239. Watanabe K, Kinoshita S, Nakagawa H: Purification and characterization of cytokine-induced neutrophil chemoattractant produced by epithelioid cell line of normal rat kidney (NRK-52E cell). *Biochemical and biophysical research communications* 1989, 161(3):1093-1099.
  240. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L *et al*: IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. *Cancer cell* 2009, 15(2):103-113.
  241. Wang D, Wang H, Brown J, Daikoku T, Ning W, Shi Q, Richmond A, Strieter R, Dey SK, DuBois RN: CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. *The Journal of experimental medicine* 2006, 203(4):941-951.
  242. le Rolle AF, Chiu TK, Fara M, Shia J, Zeng Z, Weiser MR, Paty PB, Chiu VK: The prognostic significance of CXCL1 hypersecretion by human colorectal cancer epithelia and myofibroblasts. *Journal of translational medicine* 2015, 13:199.

